Journal articles: 'Unitarian Educational Directors Association'

1

Blackshaw, Stella L., and Paul G. R. Patterson. "The Prevention of Sexual Exploitation of Patients: Educational Issues*." Canadian Journal of Psychiatry 37, no. 5 (June 1992): 350–53. http://dx.doi.org/10.1177/070674379203700509.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Al-Maharmah, Yaseen Ali Mahjoub. "The Applied Strategic Planning for the Jordan Football Association from the Perspective of the Professional Clubs’ Boards of Directors (for the 2020/2021 season)." Dirasat: Educational Sciences 50, no. 2 (June 19, 2023): 91–104. http://dx.doi.org/10.35516/edu.v50i2.4532.

Full text

Abstract:

Objectives: This study aims to identify the applied strategic planning of the Jordan Football Association from the perspective of the boards of directors of professional clubs for the season 2020/2021, considering their educational qualifications and experience. Methods: The researcher used the descriptive survey method. The study sample consisted of 88 members of the boards of directors committee. The data collection was based on four basic dimensions: commitment to strategic planning, the spread of the strategic planning role, clarity of the concept of strategic planning, and availability of good standards in the components and elements of the strategic plan. Results: Based on the variables of educational qualification and experience, it was found that there was a significant correlation between holding a postgraduate degree and having more experience. Conclusions: The study emphasizes the importance for members of the Jordan Football Association to increase their awareness and enhance the efficiency of proper strategic planning processes before the launch of the sports season each year.

APA, Harvard, Vancouver, ISO, and other styles

3

Roth, Christine G., William Y. Huang, Andrew C. Caruso, Navdeep Sekhon, Doris H. Kung, Jocelyn T. Greely, Ye B. Du, et al. "How to Teach Laboratory Stewardship in the Undergraduate Medical Curriculum?" American Journal of Clinical Pathology 153, no. 1 (August 15, 2019): 66–73. http://dx.doi.org/10.1093/ajcp/aqz102.

Full text

Abstract:

Abstract Objectives Promotion of high-quality care at a lower cost requires educational initiatives across the continuum of medical education. A needs assessment was performed to inform the design of an educational tool with the goal of teaching laboratory stewardship to medical students. Methods The needs assessment consisted of semistructured interviews with core clerkship directors and residency program directors at our institution, a national survey to the Undergraduate Medical Educators Section (UMEDS) of the Association of Pathology Chairs, and a review of existing online resources that teach high-value care. Results Two major themes emerged regarding opportunities to enhance laboratory stewardship education: appropriate ordering (knowledge of test indications, pretest/posttest probability, appropriateness criteria, recognition of unnecessary testing) and correct interpretation (understanding test specifications, factors that affect the test result, recognizing inaccurate results). Conclusions The online educational tool will focus on the curricular needs identified, using a multidisciplinary approach for development and implementation.

APA, Harvard, Vancouver, ISO, and other styles

4

Jaglowski, Samantha, Zhen-Huan Hu, Yiyun Zhang, Manali Kamdar, Monalisa Ghosh, Premal Lulla, Joshua Sasine, et al. "Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry." Blood 134, Supplement_1 (November 13, 2019): 766. http://dx.doi.org/10.1182/blood-2019-130983.

Full text

Abstract:

Introduction Tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immunotherapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. In the pivotal JULIET trial, 115 patients received tisagenlecleucel treatment; the best overall response rate (ORR) was 54% and complete response (CR) rate was 40%. At a median follow-up of 24 months, the median duration of response was not reached. Grade 3 or higher cytokine release syndrome (CRS) (UPenn scale) and neurotoxicity within the first 8 weeks after infusion occurred in 22.6% and 11.3%, respectively (Bachanova et. al. Hematol Oncol. Abstr 2019). CIBMTR CT Registry was developed to collect long-term safety and efficacy information on recipients of cellular immunotherapies and it is utilized for a post marketing study of tisagenlecleucel in the real-world setting. Methods Clinical data from the registry were analyzed for baseline information. Efficacy and safety data were collected from patients with a minimum of 3 months follow-up. CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were reported as per the consensus ASTCT criteria. Important manufacturing product characteristics of tisagenlecleucel were compared to clinical outcomes obtained by the CIBMTR CT registry. The association of number of cells administered, cell viability, potency, and transduction efficiency to overall response, CRS and ICANS grade was performed using descriptive summaries and univariate logistic regression analyses. Tisagenlecleucel cell product characterization by immunophenotyping was also compared to clinical outcomes in the CIBMTR Registry. Results Twenty-six centers contributed data for relapsed/refractory DLBCL patients through the CIBMTR CT registry as of May 31, 2019. Baseline information was available in 70 patients while outcomes ≥ 3 months post-infusion was available on 47 patients (Table 1). All patients received cells in the FDA approved range (0.6 to 6 x 108 CAR+ viable T cells) with a median of 1.7 x 108 (range 0.6-3.5 x 108). The median follow-up time for survivors was 5.8 months (0.9-8.9 months). The overall response rate (ORR) was 59.6% (28 of 47 patients) including 38.3% (18 patients) achieving a CR. The rate of grade 3 or higher CRS and ICANS was 4.3% and 4.3%, respectively. Tocilizumab and corticosteroids were administered in 40.9% and 9.1% among patients who had CRS. The median time to onset of CRS was 4.5 days and lasted for an average of 5 days. A total of 14 (29.8%) patients died after treatment, all due to disease progression and no deaths were attributed to toxicities from tisagenlecleucel. A secondary malignancy was reported in 1 patient (basal cell carcinoma) that was present prior to CAR-T cell infusion. Out of the products manufactured for these 47 patients, 21 were out-of-commercial specification (OOS) because of low cell viability (< 80%), however, efficacy and safety outcomes were similar to those with batches meeting viability specifications. None of the manufacturing characteristics analyzed (such as cell viability, potency or transduction efficiency) correlated with either efficacy (ORR) or safety (CRS or ICANS). Importantly, analysis of cell viability showed no association with best overall response (Table 2). Conclusions The CIBMTR CT registry represents real-world data for the treatment of adults with DLBCL and allows capture of long-term follow up (15 years). The efficacy and safety in the real world setting demonstrate similar efficacy and safety as compared with the pivotal JULIET trial. Cell product characteristics analyzed, including percentage of viable cells, do not correlate with response rates, CRS or ICANS. Updated results, including tisagenlecleucel cell product characterization, will be presented at the meeting. Disclosures Kamdar: Seattle Genetics: Speakers Bureau; Pharmacyclics: Consultancy; Celgene: Consultancy; AstraZeneca: Consultancy; University of Colorado: Employment. Perales:Medigene: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Kyte/Gilead: Research Funding; Miltenyi: Research Funding; Merck: Consultancy, Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; MolMed: Membership on an entity's Board of Directors or advisory committees; NexImmune: Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bellicum: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Meyers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Nektar Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Omeros: Honoraria, Membership on an entity's Board of Directors or advisory committees. Nikiforow:Kite/Gilead: Honoraria; Novartis: Honoraria; NKarta: Honoraria. Jeschke:Novartis: Employment. Chawla:Novartis Pharma AG: Employment. Horowitz:Mesoblast: Other: Unrestricted educational and research grant, Research Funding; Gamida Cell: Other: Unrestricted educational and research grant, Research Funding; Chimerix: Other: Unrestricted educational and research grant; Janssen: Other: Unrestricted educational and research grant, Research Funding; Pharmacyclics: Other: Unrestricted educational and research grant; Daiichi Sankyo: Other: Unrestricted educational and research grant; Miltenyi Biotech: Other: Unrestricted educational and research grant, Research Funding; CSL Behring: Other: Unrestricted educational and research grant, Research Funding; Regeneron: Other: Unrestricted educational and research grant; Sanofi: Other: Unrestricted educational and research grant, Research Funding; Bristol-Myers Squibb: Other: Unrestricted educational and research grant, Research Funding; Seattle Genetics: Other: Unrestricted educational and research grant; Actinium: Other: Unrestricted educational and research grant; GlaxoSmithKline: Other: Unrestricted educational and research grant; Amgen: Other: Unrestricted educational and research grant; Kite Pharma/Gilead: Other: Unrestricted educational and research grant, Research Funding; Magenta: Consultancy, Other: Unrestricted educational and research grant; Shire: Other: Unrestricted educational and research grant; Oncoimmune: Other: Unrestricted educational and research grant. Bleickardt:Novartis: Employment. Pasquini:Pfizer: Other: Advisory Board; Amgen: Consultancy; Medigene: Consultancy; BMS: Research Funding; Kit Pharma: Research Funding; Novartis: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

5

He, Ren, Mingdian Zhou, Jing Liu, and Qing Yang. "Female Directors and Carbon Information Disclosure: Evidence from China." Discrete Dynamics in Nature and Society 2021 (September 2, 2021): 1–16. http://dx.doi.org/10.1155/2021/7772601.

Full text

Abstract:

In recent years, natural disasters and public health events caused by global warming have occurred frequently around the world. It has become a global consensus to actively respond to climate change. Firms are the main source of greenhouse gas emissions. The disclosure of carbon information is one of the most important ways for firms to respond to climate change. The effect of female directors on carbon information disclosure is still unclear. Considering that China is the largest country in greenhouse gas emissions and the social status of females in China is different from western countries, this paper explores the effect of female directors on carbon information disclosure by firms in China. Based on the sample of listed Chinese firms in high carbon industries during the period of 2012–2017, our empirical results show that female directors have a positive association with carbon information disclosure. In addition, we find that the power, educational level, and financial background of female directors have positive impacts on firms’ carbon information disclosure. Our findings make a significant contribution to the ongoing debate on the role of female directors and provide new insights and policy implications for firms, regulators, and other stakeholders.

APA, Harvard, Vancouver, ISO, and other styles

6

Cathers, Lauretta, Kieran Fogarty, Lynda T. Goodfellow, Christina B. Gunther, Beverly W. Henry, Douglas A. Kuperman, Laura Santurri, and G. Zipp. "Toward an Identity for the Field of Doctoral Education in Health Sciences." Journal of Innovation in Health Sciences Education 1, no. 2 (April 30, 2024): 1–6. http://dx.doi.org/10.46409/003.sydw2348.

Full text

Abstract:

The Association of Doctoral Programs in Health Sciences (ADPHS) was informally established in November 2019, officially incorporated in August 2021, and is currently a 501(c)(3) nonprofit organization comprised of the directors of member doctoral programs of health sciences. The ADPHS grew from informal discussions among program directors who agreed that a major problem in the field of doctoral education in health sciences was the lack of a clearly defined and easily articulable identity. The discussions led to the drafting of an informal and nonscientific survey used to help clarify the current health sciences education environment, relevant emerging trends, and the educational philosophies adopted by the directors of health sciences doctoral programs nationally. The results of the survey and follow-up discussions revealed a strong consensus among program directors that the field of doctorate education in health sciences is uniformly characterized by its interdisciplinary nature. In this position paper, we provide the rationale for the formal position of the ADPHS that the identity of the field of doctoral education in health sciences is based on its interdisciplinary approach to education.

APA, Harvard, Vancouver, ISO, and other styles

7

Schnobrich, Daniel J., Sophie Gladding, Andrew P. J. Olson, and Alisa Duran-Nelson. "Point-of-Care Ultrasound in Internal Medicine: A National Survey of Educational Leadership." Journal of Graduate Medical Education 5, no. 3 (September 1, 2013): 498–502. http://dx.doi.org/10.4300/jgme-d-12-00215.1.

Full text

Abstract:

Abstract Background Ultrasound is a valuable tool in the safe performance of an increasing number of procedures. It has additionally emerged as a powerful instrument for point-of-care assessment by offering internists an opportunity to extend their traditional physical examination. Objective This study explored how internal medicine (IM) educators perceive the use of ultrasound for procedures and point-of-care assessments, the extent to which curricula for teaching IM residents ultrasound skills exist, and perceived barriers to teaching its use. Methods In February 2012, we administered a 27-question survey to all members of the Association of Program Directors in Internal Medicine, eliciting their opinions about the use of point-of-care ultrasound. Results Of 2200 surveys distributed electronically, 234 were returned (a 11% response rate), including 167 by program directors or assistant program directors. Respondents highly rated the usefulness of ultrasound for central-line placement, thoracentesis, paracentesis, and diagnosis of pleural effusions. Evaluation of vena cava and heart, and placement of radial artery catheters received somewhat lower usefulness scores. Forty-five respondents (25%) reported having formal curricula to teach point-of-care ultrasound, and 46 respondents without current ultrasound programs were planning to initiate them in the next 12 months. Potential barriers to teaching and use of ultrasound included the time and cost to train faculty, the cost of ultrasound machines, and the time required to train residents. Conclusions Educational leaders in IM view point-of-care ultrasound as a valuable tool in diagnosis and procedures, and many residency programs are teaching these skills to their learners.

APA, Harvard, Vancouver, ISO, and other styles

8

Carnine, Doug. "Bridging the Research-to-Practice Gap." Exceptional Children 63, no. 4 (June 1997): 513–21. http://dx.doi.org/10.1177/001440299706300406.

Full text

Abstract:

The contribution of research findings to the education of Americas students, including those with disabilities, depends on the quality of and market demand for research findings. This paper presents a rationale and suggestions for increasing the quality of and market demand for research findings as a vital component of any serious effort to improve American education. Responses to the paper are from representatives of the American Federation of Teachers; Learning Disabilities Association; National Alliance of Business; National Association of State Directors of Special Education; and Staff Director, Disability Policy Subcommittee, U.S. Senate. An additional response, which also synthesizes all responses, is provided by The Council for Exceptional Children.

APA, Harvard, Vancouver, ISO, and other styles

9

Covassin, Tracey, Robert Elbin, and Jennifer L. Stiller-Ostrowski. "Current Sport-Related Concussion Teaching and Clinical Practices of Sports Medicine Professionals." Journal of Athletic Training 44, no. 4 (July 1, 2009): 400–404. http://dx.doi.org/10.4085/1062-6050-44.4.400.

Full text

Abstract:

Abstract Various consensus and position statements recommend a multifaceted approach when diagnosing a possible concussion. The effectiveness of these materials depends largely on their content being disseminated to educators and to those in the clinical setting.Context: To identify the concussion management methods and guidelines currently taught in the athletic training classroom and clinical settings and to track the dissemination of the Vienna guidelines throughout the educational curriculum.Objective: A 17-question Internet survey.Design: A Web link was e-mailed to the program directors and certified athletic trainers holding educational positions in athletic training at 300 accredited programs in the United States.Setting: 513 program directors and athletic trainers.Patients or Other Participants: Survey questions addressed education level, years of certification, employment setting, concussion assessment and return-to-play guidelines used in the clinical setting and the classroom, and clinical and teaching preferences for existing position statements and concussion grading systems. The Vienna guidelines' “simple” and “complex” definitions of concussions were provided with the return-to-play stepwise approach.Main Outcome Measure(s): The National Athletic Trainers' Association position statement was the most widely used method of assessing, managing (61%), and making return-to-play decisions (47%) among participants. More than half of participants (66%) had never heard of the Vienna guidelines. After reading the Vienna guidelines' definitions and return-to-play criteria, nearly three-fourths of participants agreed with them. In addition, 68% said that they would use them, and 84% reported that they would teach them to students.Results: The majority of program directors and certified athletic trainers used a multidimensional approach to assess and manage a concussion. The National Athletic Trainers' Association position statement and Vienna guidelines were underused in both the classroom and clinical settings.Conclusions:

APA, Harvard, Vancouver, ISO, and other styles

10

Cogen, Jonathan D., Alexandra Perkins, Blair Mockler, Krysta S. Barton, Alan Schwartz, Markus Boos, Anjana Radhakrishnan, et al. "Pediatric Resident and Program Director Views on Climate Change and Health Curricula: A Multi-Institution Study." Academic Medicine 99, no. 6 (January 12, 2024): 654–62. http://dx.doi.org/10.1097/acm.0000000000005633.

Full text

Abstract:

Abstract Purpose The American Academy of Pediatrics emphasized in a 2007 policy statement the importance of educating trainees on the impacts of climate change on children’s health, yet few studies have evaluated trainee knowledge and attitudes about climate change–related health effects in children. This multi-institution study assessed pediatric resident and program director (1) knowledge/attitudes on climate change and health, (2) perspectives on the importance of incorporating climate and health content into pediatric graduate medical education, and (3) preferred topics/activities to include in climate and health curricula. Method This mixed-methods study employed an anonymous cross-sectional survey of pediatric residents and residency program directors from Association of Pediatric Program Directors (APPD) Longitudinal Educational Assessment Research Network (LEARN)–affiliated programs. Multivariable regression models and factor analyses were used to examine associations among resident demographics and resident knowledge, attitudes, and interest in a climate change curriculum. A conventional content analysis was conducted for the open-ended responses. Results Eighteen programs participated in the study with all program directors (100% response rate) and 663 residents (average response rate per program, 53%; overall response rate, 42%) completing respective surveys. Of the program directors, only 3 (17%) felt very or moderately knowledgeable about the association between climate change and health impacts. The majority of residents (n=423, 64%) agreed/strongly agreed that physicians should discuss global warming/climate change and its health effects with patients/families, while only 138 residents (21%) agreed/strongly agreed that they were comfortable talking with patients and families about these issues. Most residents (n=498, 76%) and program directors (n=15, 83%) agreed/strongly agreed that a climate change curriculum should be incorporated into their pediatrics training program. Conclusions Pediatric residents and program directors support curricula that prepare future pediatricians to address the impact of climate change on children’s health; however, few programs currently offer specific training, despite identified needs.

APA, Harvard, Vancouver, ISO, and other styles

11

Oliver-Caldés, Aina, Marta Español-Rego, Aintzane Zabaleta, Susana Inogés, Ascensión López-Diaz de Cerio, Veronica Gonzalez-Calle, Valentin Cabañas, et al. "Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)." Blood 138, Supplement 1 (November 5, 2021): 552. http://dx.doi.org/10.1182/blood-2021-148281.

Full text

Abstract:

Abstract B ackground: ARI0002h is an academic autologous CAR T-cell product with a 4-1BB co-stimulatory domain and a humanized single chain variable fragment targeting BCMA, which is being tested in the CARTBCMA-HCB-01 clinical trial for patients (pts) with RRMM (NCT04309981). A fractionated infusion of 3x10 6 CAR+ cells (ARI0002h)/kg (10/30/60%) was administered after lymphodepletion regimen (LR). A second dose of 3x10 6 CAR+ cells/kg was planned starting at 4 months after the first dose, with or without LR according to persistence of CAR-T in peripheral blood (PB). Clinical results have been submitted in a separate abstract (#147188); here we present the correlative biological studies performed and related to disease response. Methods: ARI0002h production data were obtained and analyzed, including % CAR transduction in the final product (FP) by flow cytometry (FC). PB samples were obtained at inclusion and sequentially after infusion. Bone marrow (BM) samples were obtained at inclusion, at d28, d100 and at 6 months (m), to evaluate BCMA expression on plasma cells (PCs) and minimal residual disease (MRD) by next generation flow (NGF) with 10 -6 sensitivity. Apheresis, FP, and PB/BM samples on d28 were analyzed for T-cell subpopulations and surface markers. Persistence of ARI0002h was evaluated in PB after infusion by PCR. If a second infusion was administered, CART detection after 3 and 7d was also checked. Plasmatic soluble BCMA (sBCMA) was determined by ELISA prior to infusion, at d28 and if a relapse was observed. Human anti-human antibodies (HAHAs) were evaluated at d100 (using FC on transduced HEK cells). Clinical and response data were collected for analysis. Results: Mean BCMA molecules/cell on malignant BM PC at inclusion were 1306 (SD ±889) with non-significant (NS) correlation with response at d100. Thirty-three apheresis were obtained and transduced, with a median manufacturing time of 11d (range 9-14). All FP were successfully obtained at first attempt but one, which could be produced with a second apheresis. The mean % transduction of ARI0002h on autologous T cells was 56% (SD ±25). A higher CD4/CD8 ratio in the apheresis was correlated with achievement of stringent complete response (sCR) (p=0.003); this association was not observed in the FP. Moreover, T-cell subpopulations in the FP did not correlate with response (Figure 1A). A significant increase of PD-1 (p=0.0001), TIGIT (p=0.037) and LAG3 (p=0.003) expression was observed in CD4 CAR-T cells, as well as PD-1 in CD8 (p=0.0001), between the FP and d28 PB paired samples; similar results were observed in BM CAR-T cells at d28, except for LAG3 (Figure 1B). ARI0002h CAR-T cells showed maximum PB expansion at 14d (range 7d - 5m). Among pts with 3 and 6 m follow-up, 54% and 24% had evidence of CAR+ T cells in PB, with a median persistence of 4m (range 2-not reached). Expansion levels by PCR and PB persistence did not correlate with MM response. 22 out of 27 eligible pts (81%) received a 2 nd dose, with a subsequent CART expansion in 10 of 20 (50%) evaluable pts; LR was readministered in only 30% of these 10 pts. B-cell aplasia was observed in all pts concurring with CART expansion (Figure 1C). Also, a decline in B-cell counts was observed in some pts after reinfusion, with no association with response. Patients with detectable sBCMA at inclusion became sBCMA negative in all the subsequent tested samples at d28 and d100. None of these pts have relapsed. 27 pts had MRD assessed at day +100. In 3, the BM was severely hemodiluted and inadequate for MRD testing. Of 24 MRD-evaluable pts, 22 (92%) were MRD-negative (59% were negative at a sensitivity of 1x10 -6, 36% at 1x10 -5 and 5% at 1x10 -4), and 2 were MRD positive (one BCMA positive and another with BCMA undetermined result). Only 1 of 27 (4%) evaluable pts had positive HAHAs at day 100. CAR-T cells were undetectable at day 70 in this patient, but after receiving a 2 nd dose at m4 a short-lasted expansion was observed. Despite that, the patient deepened the response from partial response (PR) (d100) to very good PR (m6). Conclusion: ARI0002h production is fast and feasible. The peak of CART expansion occurs after 14d of infusion and also in some pts after reinfusion, regardless of LR, which suggests that LR may not be mandatory to allow further expansion after booster dose. Responses obtained are deep and construct immunogenicity seems to be low. Figure 1 Figure 1. Disclosures Gonzalez-Calle: BMS, Janssen, Amgen: Honoraria. Cabañas: Sanofi: Honoraria; BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Reguera: Janssen, Kite/Gilead, Novartis: Speakers Bureau; BMS-Celgene, Novartis: Membership on an entity's Board of Directors or advisory committees. Rodríguez-Otero: Regeneron: Honoraria; Celgene-BMS, Janssen, Amgen, Sanofi, GSK, Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees. Rosinol: Janssen, Celgene, Amgen and Takeda: Honoraria. Moraleda: Pfizer: Other: Educational Grants, Research Funding; Sanofi: Other: Educational Grants, Research Funding; MSD: Other: Educational Grants, Research Funding; ROCHE: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Takeda: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Sandoz: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Gilead: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Educational Grants, Research Funding; NovoNordisk: Other: Educational Grants, Research Funding; Janssen: Other: Educational Grants, Research Funding; Celgene: Other: Educational Grants, Research Funding; Amgen: Other: Educational Grants, Research Funding. Prósper: Oryzon: Honoraria; Janssen: Honoraria; BMS-Celgene: Honoraria, Research Funding. Mateos: Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria; GSK: Honoraria; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird bio: Honoraria; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees. Paiva: Bristol-Myers Squibb-Celgene, Janssen, and Sanofi: Consultancy; Adaptive, Amgen, Bristol-Myers Squibb-Celgene, Janssen, Kite Pharma, Sanofi and Takeda: Honoraria; Celgene, EngMab, Roche, Sanofi, Takeda: Research Funding. Fernandez de Larrea: GSK: Honoraria; Takeda: Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy; Janssen: Consultancy, Honoraria, Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

12

Dvoryanchikov, N. V., S. V. Budykin, E. S. Avdeev, and I. B. Bovina. "Professionalism in the work of the Director of the school: features of ordinary representations of groups of principals, teachers and parents." Psychology and Law 6, no. 3 (2016): 1–13. http://dx.doi.org/10.17759/psylaw.2016060301.

Full text

Abstract:

The purpose of the study was to identify and analyze everyday notions of professionalism in activities of the school Director. The object of the research – group of adults associated with the educational process. The sample consisted of Directors and Deputy Directors of a number of Moscow schools, teachers, and parents of students. The total sample size was 166 persons (N=55 principals and Vice, N=57 teachers, N=54 parents) at the age from 22 to 68 years. The object of research – features of everyday notions of professionalism in activities of the school Director. We put forward a General assumption that the groups of Directors, parents and teachers will vary the ratio of functional and regulatory elements; in the group of Directors in the idea of professionalism will dominate the functional elements in the group of teachers is expected to identify both the normative and functional elements, the group of parents – mostly normative. The main research method was a survey. For its implementation was drawn up a questionnaire. In accordance with the theory of social representations within which we developed the research, the key methodology was the technique of free Association. Our hypothesis received partial empirical support. The results are discussed from the point of view of the theory of social representations.

APA, Harvard, Vancouver, ISO, and other styles

13

Johnson, James E., Chrysostomos Giannoulakis, and Beau F. Scott. "Interscholastic Competitive Balance: An Examination of State Athletic Association Administrators." Journal of Sport Management 31, no. 3 (May 2017): 256–74. http://dx.doi.org/10.1123/jsm.2016-0226.

Full text

Abstract:

While competitive balance literature is robust when addressing professional sport from an economic perspective, little empirical work has focused on understanding what shapes interscholastic competitive balance policies. Using the theory of distributive justice as a framework, the purpose of this multiple case study was to examine the perceptions of top administrators regarding sociocultural influences on interscholastic competitive balance. Qualitative interview data collected from six state commissioners/executive directors revealed four predominant findings: (a) policy is driven by a philosophical approach that is aligned with the theory of distributive justice; (b) an overemphasis on winning strongly influences policy; (c) political influence through legal threats and state educational policy shapes committee decisions; and (d) the prevailing challenges of policy creation include school size, geography, public/nonpublic status, tradition, sport-specific characteristics, and lack of knowledge. Implications of these findings are discussed.

APA, Harvard, Vancouver, ISO, and other styles

14

Rosinol, Laura, Albert Oriol, Rafael Ríos Tamayo, María Jesús Blanchard, Isidro Jarque, Joan Bargay, Miguel-Teodoro Hernández, et al. "Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial." Blood 138, Supplement 1 (November 5, 2021): 466. http://dx.doi.org/10.1182/blood-2021-146798.

Full text

Abstract:

Abstract Background: The Spanish Myeloma Group (GEM) demonstrated that post-transplant maintenance with thalidomide plus bortezomib was superior to thalidomide alone, although this combination was associated with a high rate of peripheral neuropathy. Lenalidomide is currently the standard postransplant maintenance treatment, and its association with ixazomib, an oral proteasome inhibitor that does not cause peripheral neuropathy, could be of interest. Aim: To assess the potential benefit of postransplant maintenance therapy with Ixazomib /lenalidomide/dexamethasone (IRd) over lenalidomide/dexamethasone (Rd). Patients: Patients who where at least with stable disease after the GEM2012menos65 trial that included VRD-GEM induction, autologous hematopoietic stem cell transplantation conditioned with either melphalan-200 or intravenous busulfan together with melphalan-140 and consolidation with VRD-GEM were randomized to receive maintenance treatment with IRd versus Rd. Each cycle lasted 28 days. Rd arm consisted of lenalidomide 15 mg/d on days 1-21 and 20mg of dexamethasone administered orally on days 1-4 and 9-12. In IRd arm ixazomib 4 mg/day on days 1, 8 and 15 of the cycle was added. At two years, patients with negative MRD discontinued maintenance treatment. Patients with positive MRD continued with Rd for 3 additional years. In this case, 20 mg of dexamethasone was only administered on days 1-4 of the cycle. From November 24, 2014 to May 18, 2017, 161 patients were allocated to Rd arm and 171 to IRd arm. Patient characteristics at screening and prognostic factors such as ISS, cytogenetics and plasmacytomas, as well as response status, were similarly distributed in the two arms. Overall, 22% of the patients had high-risk cytogenetics [t(4;14), t(14;16) and/or 17p deletion]. MRD was analyzed by using next-generation flow at a sensitivity level of 3x10 -6. Results: After a median follow-up of 56 months, there was no difference in PFS between the two maintenance arms (median not reached, PFS at 5 years: 62% vs. 63% with IRd and Rd, respectively, p=0.785) (figure 1). In the overall series, there were no significant differences in PFS or OS among patients with standard (SR) or high-risk (HR) cytogenetics. Median PFS had not been reached in patients with SR in both arms (PFS at 5 years: 66% with IRD vs. 62% with Rd, p=0.633). In patients with HR the median PFS was 62 months with IRd vs. not reached with Rd (p=0.636). No significant differences across subgroups (ISS, conditioning, cytogenetics or MRD) were observed between IRd and Rd. Negative MRD at screening overcomes the bad prognosis of cytogenetics (PFS at 5 years 78% for SR and 80% for HR; OS at 5 years was 90% for both, SR and HR). Patients with SR who had negative MRD at screening had a significantly longer PFS (PFS at 5 years 78% vs. 50%, p<0.0001) and a significantly longer OS (OS at 5 years; 90% vs. 80%, p=0.042) than patients with positive MRD. Patients with HR and positive MRD at screening had a dismal prognosis compared with patients with negative MRD (median PFS of 37 months vs. not reached, p<0.0001; OS at 5 years:70% vs. 90%, p=0.03). Patients with negative MRD at 2 years discontinued therapy with a low impact on relapse while patients with positive MRD had a higher rate of relapse despite the fact that they were receiving maintenance for 3 additional years. 73% and 65% of the patients were in sCR/CR at the time of screening and the sCR/CR rate was upgraded by 16% with IRd and 19% with Rd. Grade 3-4 neutropenia was similar in both arms (IRd: 37%, Rd:39%). However, grade 3-4 thrombocytopenia (16% vs. 7%, p=0.01) and grade 3-4 gastrointestinal toxicity (15% vs. 2%, p<0.0001) was significantly higher with IRd. 31% of the patients needed dose reductions of ixazomib and 9% discontinued the drug. There was a trend to a higher need of dose reductions of lenalidomide with IRd (IRd: 29% vs. Rd: 21%) while the need for dose reduction of dexamethasone was identical in both arms (21%). Conclusions: Maintenance therapy with lenalidomide and dexamethasone in patients homogeneously treated with VRD-GEM induction, ASCT and VRD-GEM consolidation resulted in a long PFS of 63% at 5 years from the start of maintenance. The addition of ixazomib did not result in a PFS benefit. This could be partially explained by the higher toxicity leading to dose reductions or discontinuation of ixazomib in the IRd arm. Figure 1 Figure 1. Disclosures Rosinol: Janssen, Celgene, Amgen and Takeda: Honoraria. Oriol: Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Jarque: AbbVie: Consultancy, Speakers Bureau; Alexion: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Apellis: Consultancy; AstraZeneca: Consultancy, Speakers Bureau; Beigene: Consultancy; CellTrion: Consultancy; Eusa: Consultancy; Gilead: Consultancy, Speakers Bureau; Grifols: Consultancy; Incyte: Consultancy; Janssen: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Servier: Speakers Bureau; Shionogi: Consultancy; Sobi: Consultancy; Takeda: Consultancy, Speakers Bureau. Moraleda: Pfizer: Other: Educational Grants, Research Funding; Sanofi: Other: Educational Grants, Research Funding; MSD: Other: Educational Grants, Research Funding; ROCHE: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Takeda: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Sandoz: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Gilead: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Educational Grants, Research Funding; NovoNordisk: Other: Educational Grants, Research Funding; Janssen: Other: Educational Grants, Research Funding; Celgene: Other: Educational Grants, Research Funding; Amgen: Other: Educational Grants, Research Funding. Sureda: Mundipharma: Consultancy; Bluebird: Membership on an entity's Board of Directors or advisory committees; Roche: Other: Support for attending meetings and/or travel; GSK: Consultancy, Honoraria, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite, a Gilead Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding, Speakers Bureau. Martínez-López: Roche, Novartis, Incyte, Astellas, BMS: Research Funding; Janssen, BMS, Novartis, Incyte, Roche, GSK, Pfizer: Consultancy. De Arriba: BMS-Celgene: Consultancy, Honoraria, Speakers Bureau; Glaxo Smith Kline: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Speakers Bureau. Mateos: Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird bio: Honoraria; GSK: Honoraria; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria; Oncopeptides: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. San-Miguel: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, and Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees. Lahuerta: Celgene: Other: Travel accomodations and expenses; Celgene, Takeda, Amgen, Janssen and Sanofi: Consultancy. Bladé Creixenti: Janssen, Celgene, Takeda, Amgen and Oncopeptides: Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

15

Haftel, Hilary M., Rebecca Swan, Marsha S. Anderson, Grace L. Caputo, John G. Frohna, Su-Ting T. Li, Richard P. Shugerman, et al. "Fostering the Career Development of Future Educational Leaders: The Success of the Association of Pediatric Program Directors Leadership in Educational Academic Development Program." Journal of Pediatrics 194 (March 2018): 5–6. http://dx.doi.org/10.1016/j.jpeds.2017.11.066.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Everard, Kelly M., and Kimberly Zoberi Schiel. "Changes in Family Medicine Clerkship Teaching Due to the COVID-19 Pandemic." Family Medicine 53, no. 4 (April 6, 2021): 282–84. http://dx.doi.org/10.22454/fammed.2021.583240.

Full text

Abstract:

Background and Objectives: On March 17, 2020, the Association of American Medical Colleges recommended temporary suspension of all medical student clinical activities due to the COVID-19 pandemic, which required a rapid development of alternatives to traditional teaching methods. This study examines education changes spurred by COVID-19. Methods: Data were collected via a Council of Academic Family Medicine Educational Research Alliance survey of family medicine clerkship directors. Participants answered questions about didactic and clinical changes made to clerkship teaching due to the COVID-19 pandemic, how positive the changes were, whether the changes would be made permanent, and how prepared clerkship directors were for the changes. Results: The response rate was 64%. The most frequent change made to didactic teaching was increasing online resources. The most frequent change made to clinical teaching was adding clinical simulation. Greater changes were made to clinical teaching than to didactic teaching. Changes made to didactic teaching were perceived as more positive for student learning than the changes made to clinical teaching. Clerkship directors felt more prepared for changes to didactic teaching than for clinical teaching, and were more likely to make the didactic teaching changes permanent than the clinical teaching changes. Conclusions: The COVID-19 pandemic caused nearly all clerkship directors to make changes to clerkship teaching, but few felt prepared to make these changes, particularly changes to clinical teaching. Clerkship directors made fewer changes to didactic teaching than clinical teaching, however, didactic changes were perceived as more positive than clinical changes and were more likely to be adopted long term.

APA, Harvard, Vancouver, ISO, and other styles

17

Garcés, Juan-José, Noemi Puig, Rosalinda Termini, María Teresa Cedena, Cristina Moreno, José J. Pérez, Diego Alignani, et al. "Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints." Blood 138, Supplement 1 (November 5, 2021): 76. http://dx.doi.org/10.1182/blood-2021-146535.

Full text

Abstract:

Abstract Background: CTCs may be responsible for MM spreading and accordingly, their numbers in peripheral blood (PB) could be a potential surrogate marker for the rate of dissemination and overall tumor burden in bone marrow (BM). In such case, CTCs may be a powerful biomarker of malignant transformation and disease aggressiveness. Aim: To investigate the clinical significance of CTCs in patients with smoldering (SMM), newly diagnosed (NDMM) and relapsed/refractory MM (RRMM), and to compare the transcriptional profile of CTCs across the disease spectrum. Methods: Next-generation flow (NGF) cytometry was used to assess the percentage of CTCs in PB of 1,157 patients: 316 with SMM, 650 with NDMM and 191 with RRMM. In each disease setting, patients were sub-classified into three groups with undetectable, low and high percentage of CTCs. Cutoffs were defined using maximally selected rank statistics adjusted for time to progression (TTP) in SMM and progression free survival (PFS) in NDMM/RRMM. A subset of SMM patients (n=86) was enrolled in GEM-CESAR. Transplant eligible (n=374) and ineligible (n=276) NDMM, as well as RRMM patients, were homogenously treated according to the GEM2012MENOS65, GEM-CLARIDEX and GEM-KYCYDEX clinical trials, respectively. In 40 patients (2 SMM, 33 NDMM and 5 RRMM) paired CTCs and BM tumor cells were FACSorted and their transcriptional profile was analyzed using RNAseq. Differentially expressed genes were investigated using DESeq2. Results: CTCs were detected in 248/316 (78%), 597/650 (92%) and 170/192 (89%) of SMM, NDMM and RRMM patients. Median CTC frequencies were: 0.001% (0.05 CTCs/µL), 0.01% (0.64 CTCs/µL) and 0.005% (0.22 CTCs/µL), respectively. There were 79 genes differentially expressed between patient-matched CTCs and BM tumor cells (e.g., FLNA, EMP3, LGALS9, MUC1). These were functionally related with TNFα signaling and inflammatory response (enriched in CTCs), as well as to cell cycle and MYC targets (enriched in BM tumor cells). Interestingly, the enrichment of these signatures in CTCs and BM tumor cells was progressively more pronounced from SMM to NDMM and RRMM. Altogether, these data suggest that the CTC-based dissemination potential peaks at the stage of NDMM, which could be related to greater inflammation in BM and cell cycle arrest driving tumor cell egression into PB. There were significant associations between the percentage of CTCs and the 2/20/20 IMWG risk model in SMM, the ISS in NDMM, and high-risk cytogenetics in all three-disease settings. Untreated SMM patients (n=230) with high CTC levels (≥0.02%) showed ultra-high risk of transformation vs those with low and undetectable CTCs (median TTP of 11 months vs not reached [NR] in both; P < .0001). Notably, SMM patients with ≥0.02% CTCs enrolled in GEM-CESAR have not reached a median TTP; thus, early intervention abrogated the poor prognosis of high CTC levels. Transplant-eligible NDMM patients stratified by undetectable, low and high (≥0.2%) CTC levels showed median PFS of NR, 78 and 47 months, respectively (P < .0001). Significant risk stratification was further observed in transplant ineligible NDMM (median PFS: NR, 31 and 14 months, respectively, P = .002) and RRMM (median PFS: NR, 24 and 7 months, respectively, P = .004). In untreated SMM, multivariate analysis of TTP including CTCs, serum M-component (>2 g/dL), sFLC ratio (>20) and BM plasma cells (>20%) selected CTCs as an independent prognostic factor (hazard ratio [HR]: 1.61, P = .015) together with the M-component and sFLC ratio. In NDMM, multivariate analysis of PFS including CTCs, BM plasma cells counts by morphology and flow cytometry, ISS, LDH, cytogenetics and transplant eligibility showed that high CTC levels had independent prognostic value (HR: 1.43, P = .003). Only the achievement of undetectable measurable residual disease (MRD) abrogated the poor prognosis of high CTC levels. Conclusions: This is the largest study investigating the role of CTCs in smoldering and active MM. Our results show that tumor cells are continuously trafficking in PB, possibly through a dynamic mechanism of egression that peaks in NDMM. Evaluation of CTCs in PB outperformed quantification of BM tumor burden in SMM and NDMM, and showed prognostic value in all three-disease stages. Thus, CTC assessment should be part of the diagnostic workup of MM. Early intervention in high risk SMM and undetectable MRD in NDMM may abrogate dismal outcomes associated with high CTC levels. Disclosures Puig: Amgen, Celgene, Janssen, Takeda: Consultancy; Celgene: Speakers Bureau; Celgene, Janssen, Amgen, Takeda: Research Funding; Amgen, Celgene, Janssen, Takeda and The Binding Site: Honoraria. Cedena: Janssen, Celgene and Abbvie: Honoraria. Oriol: GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Sureda: Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite, a Gilead Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GSK: Consultancy, Honoraria, Speakers Bureau; Roche: Other: Support for attending meetings and/or travel; Bluebird: Membership on an entity's Board of Directors or advisory committees; Mundipharma: Consultancy; MSD: Consultancy, Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding, Speakers Bureau. De Arriba: Amgen: Consultancy, Honoraria; Glaxo Smith Kline: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Speakers Bureau; BMS-Celgene: Consultancy, Honoraria, Speakers Bureau. Moraleda: Pfizer: Other: Educational Grants, Research Funding; Sanofi: Other: Educational Grants, Research Funding; MSD: Other: Educational Grants, Research Funding; ROCHE: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Takeda: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Sandoz: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Gilead: Consultancy, Honoraria, Other: Educational Grants, Research Funding; Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Educational Grants, Research Funding; NovoNordisk: Other: Educational Grants, Research Funding; Janssen: Other: Educational Grants, Research Funding; Celgene: Other: Educational Grants, Research Funding; Amgen: Other: Educational Grants, Research Funding. Terpos: GSK: Honoraria, Research Funding; Genesis: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Novartis: Honoraria; Janssen-Cilag: Consultancy, Honoraria, Research Funding; BMS: Honoraria; Amgen: Consultancy, Honoraria, Research Funding. Goldschmidt: Incyte: Research Funding; Adaptive Biotechnology: Consultancy; BMS: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Celgene: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Chugai: Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; GSK: Honoraria; Novartis: Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Johns Hopkins University: Other: Grant; Molecular Partners: Research Funding; MSD: Research Funding; Mundipharma: Research Funding; Dietmar-Hopp-Foundation: Other: Grant; Sanofi: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Takeda: Consultancy, Research Funding; Amgen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding. Avet-Loiseau: Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Roccaro: AstraZeneca,: Research Funding; Amgen, Celgene, Janssen, Takeda: Membership on an entity's Board of Directors or advisory committees; Associazione Italiana per la Ricerca sul Cancro (AIRC): Research Funding; European Hematology Association: Research Funding; Fondazione Regionale per la Ricerca Biomedica (FRRB), Transcan-2 ERA-NET: Research Funding. Martinez-Lopez: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Lahuerta: Celgene: Other: Travel accomodations and expenses; Celgene, Takeda, Amgen, Janssen and Sanofi: Consultancy. Ocio: Amgen: Consultancy, Honoraria; Bristol-Myers Squibb/Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Speakers Bureau; Takeda: Consultancy, Honoraria, Speakers Bureau; Sanofi: Consultancy, Honoraria; Karyopharm: Consultancy; MSD: Honoraria; Oncopeptides: Consultancy, Honoraria; Pfizer: Consultancy; Secura-Bio: Consultancy. Rosinol: Janssen, Celgene, Amgen and Takeda: Honoraria. Bladé Creixenti: Janssen, Celgene, Takeda, Amgen and Oncopeptides: Honoraria. Mateos: AbbVie: Honoraria; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Honoraria; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird bio: Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria; Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees. San-Miguel: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, and Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees. Paiva: Adaptive, Amgen, Bristol-Myers Squibb-Celgene, Janssen, Kite Pharma, Sanofi and Takeda: Honoraria; Bristol-Myers Squibb-Celgene, Janssen, and Sanofi: Consultancy; Celgene, EngMab, Roche, Sanofi, Takeda: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

18

Wirth, Fremont P. "Meeting the challenges of neurosurgery." Journal of Neurosurgery 105, no. 6 (December 2006): 807–10. http://dx.doi.org/10.3171/jns.2006.105.6.807.

Full text

Abstract:

✓The challenges faced by neurosurgery in 2006 are many. There are five principal challenges that have received a great deal of attention from the Board of Directors of the American Association of Neurological Surgeons this past year. These are the challenge of maintaining a modern, efficient, and responsive educational program for neurosurgery; the challenge of maintaining the boundaries of neurosurgical practice and preventing the incursion of subspecialty groups into the performance of neurosurgical procedures; the challenge of responding to the changing demands of society; the challenge of influencing increased reimbursement; and the challenge of creating meaningful medical liability reform. Each of these issues are discussed.

APA, Harvard, Vancouver, ISO, and other styles

19

Kirschenbaum, Robert J. "An Interview with Carolyn M. Callahan." Gifted Child Today Magazine 16, no. 3 (May 1993): 28–33. http://dx.doi.org/10.1177/107621759301600307.

Full text

Abstract:

This is the conclusion of Robert Kirschenbaum's interview with Carolyn Callahan. Dr. Callahan is Professor of Educational Studies, Curry School of Education at the University of Virginia in Charlottesville. She is Director of the University of Virginia Enrichment Program. She has been the Editor of the Journal for the Education of the Gifted, President of the Association for the Gifted, and is currently on the Board of Directors for the National Association for Gifted Children. She is on the editorial board of several journals in the field of gifted education. Her publications have often focused on the education of gifted females and the evaluation of gifted programs. In addition, she was chosen as the Outstanding Faculty Member of the Commonwealth of Virginia in 1988. Dr. Callahan was interviewed by phone from her residence in Charlottesville in June, 1990.

APA, Harvard, Vancouver, ISO, and other styles

20

Laude, Marie-Charlotte, Edith Julia, Emmanuelle Nicolas-Virelizier, Gabriel Antherieu, Violaine Safar, Philippe Rey, Emmanuelle Ferrant, et al. "Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 43–45. http://dx.doi.org/10.1182/blood-2020-138789.

Full text

Abstract:

Background: Diagnostic-to-treatment interval (DTI) was recently described as a strong prognostic factor for newly diagnosed systemic diffuse large B-cell lymphoma patients (DLBCL) with an improvement of event-free survival (EFS) for patients with a longer DTI. These results have some implications for patient selection and result interpretations in clinical trials. This association has not been previously evaluated in DLBCL Primary CNS Lymphoma (PCNSL) patients who also present a clinically aggressive disease. Patients and Methods: The cohort constited of all consecutive DLBCL PCNSL patients treated in two Hematology Departments of the University of Lyon between 1984 and 2018 (N=244). All patients had DLBCL histology at diagnosis, obtained by brain biopsy (N=235, 96%), vitrectomy (N=4, 2%) or CSF evaluation (N=5, 2%). As first line treatments, all patients but 5 (2%) received high-dose (HD) methotrexate-based chemotherapy, associated with intra-venous rituximab for 154 patients (63%) and HD cytarabine for 182 patients (75%). Consolidation treatment by whole-brain radiotherapy was performed in seventy-six patients (31%). DTI was defined as the number of days between the date of diagnosis (i.e. biopsy) and the date of treatment initiation. Association between DTI and patient characteristics was assessed by chi-square tests or Student t-tests. EFS was defined from the start of therapy to progression, relapse, or death from any cause. As we previously described, prognostic factors such as age and performance status (PS) demonstrate a time-dependent effect on overall survival (OS) in PCNSL limiting the validity of traditional Cox proportional hazard models. We thus used a piecewise Cox model to allow assessment of prognostic effect over different time periods. All survival analyses were done in univariate and multivariate settings and stratified on rituximab use during first-line therapy. Results: With a median follow-up of 73.5 months, the 5-year EFS and OS rates were 31.6% and 48.4% for whole cohort, respectively. Median DTI was 16 days (range, 1 to 67 days). Short DTI (≤16 days) was associated with a poor PS (ECOG PS 2-4, 53.3% versus 38.5%), altered Karnofsky score (<70%, 49.2% versus 32.0%) but not median of age (63 versus 64 years), CSF level, deep brain involvement, type of symptoms at diagnosis, diagnosis modality, treatment period, inclusion in clinical trial and rituximab used. However, patients with elevated LDH level presented more frequently a longer DTI (41.8% versus 32.0%). DTI was associated with MSKCC risk score but not IELSG score. For prognostic analyses, 205 patients were considered (39 patients with missing data [LDH or PS]). The 5-year EFS rates were 24.6% versus 39.4% for patients with DTI ≤ and > 16 days, respectively (Figure 1). Using a standard cox model, in univariate analyses, PS (2-4 vs. 0-1) (HR: 1.40, 95%CI, 1.00 - 1.94, P=0.045) and age (per 10-year increase) (HR: 1.19, 95%CI, 1.05-1.36, P=0.006) were associated with EFS but not DTI (≤ or > 16 days) (HR: 0.80, P=0.19), deep involvement (HR: 0.97, P=0.85) and LDH level (HR=1.02, P=0.91). In multivariate analysis, only age was associated with EFS (HR: 1.27, 95%CI, 1.11-1.46, P=0.001). Using a piecewise Cox model over two periods of time (before and after 12 months), we confirmed in multivariate analyses, the time varying effect of PS and age on EFS with a high-risk period before 12 months and no prognostic effect after 12 months (Table 1). We also observed a time-dependent effect for DTI as shown by a significant interaction with time (P=0.02) (Table 1). Indeed, longer DTI was not associated with EFS before 12 months (HR: 1.14, 95%CI, 0.74-1.76, P=0.56) however, it had a strong protective effect after 12 months (HR: 0.44, 95%CI, 0.24-0.86, P=0.02). Conclusions: In this large cohort of DLBCL PCNSL, a short DTI was mainly associated with poor PS at diagnosis. We confirmed that prognostic factors for PCNSL outcome such as age and PS had time-varying effects with a good predictability of EFS only before 12 months. However, DTI allows prediction of long-term EFS (>12 months) after first line treatment. These results could be related to different biological patterns of tumor aggressiveness. If confirmed in independent PCNSL cohorts, DTI should also be taken in consideration for patient selection and the interpretation of clinical trial results especially for long-term outcome. Disclosures Karlin: Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, personal fees; Sanofi: Honoraria; Celgene/Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, personal fees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, personal fees; GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Other: Personal fees. Salles:Autolus: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Other: Educational events; BMS: Honoraria; Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Novartis, Servier, AbbVie, Karyopharm, Kite, MorphoSys: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Roche, Janssen, Gilead, Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Epizyme: Consultancy, Honoraria. Bachy:Amgen: Research Funding; Roche, Gilead: Consultancy; Beigene: Membership on an entity's Board of Directors or advisory committees; Roche, Celgene, Amgen, Janssen, Gilead, Novartis, Sanofi: Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

21

Kohan, Lynn, Susan Moeschler, Boris Spektor, Rene Przkora, Christopher Sobey, Scott Brancolini, Sayed Wahezi, and Magdalena Anitescu. "Maintaining High-Quality Multidisciplinary Pain Medicine Fellowship Programs: Part I: Innovations in Pain Fellows’ Education, Research, Applicant Selection Process, Wellness, and ACGME Implementation During the COVID-19 Pandemic." Pain Medicine 21, no. 8 (April 29, 2020): 1708–17. http://dx.doi.org/10.1093/pm/pnaa168.

Full text

Abstract:

Abstract Background Pain fellowship programs are facing unique challenges during the COVID-19 pandemic. Restrictions from state governments and the Centers for Disease Control and Prevention have resulted in a rapidly changing and evolving learning environment for todays’ fellows. Innovative solutions must be sought to guarantee that proper education is maintained and to ensure the well-being of our trainees. Methods We assembled a panel of pain program directors who serve as officers/board members of the Association of Pain Program Directors to provide guidance and formulate recommendations to pain fellowship directors nationally. This guidance is based on reviewing current changes to the Accreditation Council for Graduate Medical Education (ACGME) and American Board of Anesthesiology policies and best available evidence and expert opinion on the use of remote educational activities, research endeavors, and trainee wellness. Conclusions The country is in the midst of an unprecedented pandemic. The impact on pain management fellowships has been severe and will likely last for months, resulting in extraordinary challenges to the administration of pain fellowship programs and the education of our fellows. Understanding revisions to ACGME policies, using technology to promote remote learning opportunities, and providing trainees with opportunities to alleviate their anxiety and encourage mental health are beneficial strategies to implement. Together, we can implement innovative solutions to help overcome these challenges.

APA, Harvard, Vancouver, ISO, and other styles

22

Spyropoulos, Alex C., Gary E. Raskob, Alexander T. Cohen, Walter Ageno, Jeffrey I. Weitz, Theodore E. Spiro, Wentao Lu, Concetta Lipardi, and Elliot S. Barnathan. "Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial." Blood 134, Supplement_1 (November 13, 2019): 2441. http://dx.doi.org/10.1182/blood-2019-122930.

Full text

Abstract:

Background: Venous thromboembolism (VTE) is common after hospitalization in acutely ill medical patients, yet extended thromboprophylaxis has not been widely implemented due to concerns about bleeding. The MAGELLAN study (NCT00571649) evaluated whether rivaroxaban (10 mg QD for 35±4 days) compared with enoxaparin (40 mg QD for 10±4 days) followed by placebo could prevent asymptomatic deep vein thrombosis, symptomatic VTE, and VTE-related death. Through Day 35, rivaroxaban was superior to enoxaparin/placebo in the modified intent-to-treat population (4.4% vs 5.7%, RR 0.77, 95%CI, 0.62 to 0.96, p=0.02), but there was an increase in clinically relevant bleeding, the composite of major and non-major clinically relevant (NMCR) bleeding (4.1% vs 1,7%, RR 2.5, 95%CI 1.85-3.25, p<0.001). Although major bleeding has been associated with increased mortality, the relationship between NMCR bleeding and all-cause mortality (ACM) is not established. We hypothesized that subjects in the MAGELLAN trial with major bleeding but not those with NMCR bleeding, would be at an increased risk of ACM irrespective of treatment group. Methods: We evaluated all bleeding events in subjects taking at least one dose of study drug from randomization until 2 days after the last dose (safety population) and their association with ACM through the Day 90 visit in 3 mutually exclusive groups: (1) subjects with no major or NMCR bleeding; (2) subjects whose first event was NMCR bleeding; and (3) subjects whose first event was major bleeding. Subjects only developing minimal or trivial bleeding were grouped with those who had no clinically relevant bleeding. Using a Cox proportional hazards model that included the bleeding group variable and baseline covariates significantly associated with ACM at p<0.05 (age, BMI, history of cancer, history of anemia, inflammatory disease, acute ischemic stroke, and acute respiratory insufficiency), we compared the risk of ACM in subjects with and without bleeding events. Results: The incidence of ACM for subjects who had NMCR bleeding was numerically higher but not significantly increased compared with subjects with no bleeding (20/176, 11.4% vs 468/7763, 6.0%, HR 1.41 95%CI 0.88, 2.25, p=0.151), while subjects with major bleeding were at a significantly increased risk of death (28/59, 47.5% vs 468/7763, 6.0%, HR 7.74 95%CI 5.16, 11.59, p<0.0001). Results of landmark analyses from the first bleeding event or end of treatment + 2 days to ACM for the three groups are displayed (Figure). Limitations: This analysis was post hoc and may have been underpowered to detect differences in ACM associated with NMCR bleeding. Conclusion: Major bleeding was associated with a significantly increased risk of ACM but NMCR bleeding was not. This suggests that a modest increase in NMCR bleeding associated with extended thromboprophylaxis with rivaroxaban may be acceptable to prevent VTE. Strategies to better select patients at lower risk of bleeding may improve the benefit risk profile of extended thromboprophylaxis with rivaroxaban. Disclosures Spyropoulos: Daiichi Sankyo: Consultancy; Boehringer Ingelheim: Consultancy, Research Funding; Portola: Consultancy; Bayer Healthcare: Consultancy; ATLAS (Colorado Prevention Center): Consultancy; Janssen R&D, LLC: Consultancy. Raskob:Janssen R&D, LLC: Consultancy, Honoraria; Novartis: Consultancy; Tetherex: Consultancy; Daiichi Sankyo: Consultancy, Honoraria; Anthos: Consultancy; Boehringer Ingelheim: Consultancy; Pfizer: Consultancy, Honoraria; Portola: Consultancy; Bayer Healthcare: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Eli Lilly: Consultancy. Cohen:Boston Scientific: Consultancy; CSL Behring: Consultancy; GlaxoSmithKline: Consultancy, Speakers Bureau; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Boehringer-Ingelheim: Consultancy, Speakers Bureau; GLG: Consultancy; AbbVie: Consultancy; ACI Clinical: Consultancy; Aspen: Consultancy, Speakers Bureau; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Guidepoint Global: Consultancy; Johnson and Johnson: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Leo Pharma: Consultancy; Medscape: Consultancy, Speakers Bureau; McKinsey: Consultancy; Navigant: Consultancy; ONO: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Portola: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy; Temasek Capital: Consultancy; TRN: Consultancy; UK Government Health Select Committee: Other: advised the UK Government Health Select Committee, the all-party working group on thrombosis, the Department of Health, and the NHS, on the prevention of VTE; Lifeblood: Other: advisor to Lifeblood: the thrombosis charity and is the founder of the European educational charity the Coalition to Prevent Venous Thromboembolism. Ageno:Boehringer Ingelheim: Membership on an entity's Board of Directors or advisory committees, Other: conference and travel support; Bayer: Membership on an entity's Board of Directors or advisory committees, Other: research support,travel support ; BMS Pfizer: Other: travel support; Aspen: Membership on an entity's Board of Directors or advisory committees, Other: travel support; Portola: Membership on an entity's Board of Directors or advisory committees, Other: travel support; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees, Other: travel support; Sanofi: Membership on an entity's Board of Directors or advisory committees, Other: travel support. Weitz:Janssen R&D, LLC: Consultancy; Bayer Healthcare: Consultancy, Honoraria; Boehringer Ingelheim: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Daiichi-Sankyo: Consultancy, Honoraria; Ionis: Consultancy, Honoraria; Merck: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Portola: Consultancy, Honoraria. Spiro:Bayer U.S. LLC: Employment, Equity Ownership. Lu:Janssen R&D, LLC: Employment, Equity Ownership. Lipardi:Janssen Research and Develompent: Employment, Equity Ownership. Barnathan:Janssen Research and Development LLC: Employment, Equity Ownership. OffLabel Disclosure: Rivaroxaban is a Factor Xa inhibitor. It is currently under review by FDA for approval as thromboprophylaxis in acutely ill medical patients at risk for venous thromboembolism.

APA, Harvard, Vancouver, ISO, and other styles

23

Kumohin, Aleksandr, and Ruslan Kachaev. "Educational complexes as a stage of reform general education – is optimization for the good?" Applied psychology and pedagogy 6, no. 4 (October 4, 2021): 173–82. http://dx.doi.org/10.12737/2500-0543-2021-6-4-173-182.

Full text

Abstract:

The article considers the issues of the processes of merging, consolidation, and unification of various educational organizations (preschool educational organizations and municipal general education schools) into educational complexes (on the example of Moscow and the Moscow region). The accumulated experience of the existence of educational complexes is summarized, the positive and negative aspects of the association of educational organizations in general education are described. Among some positive results, the availability and opening of additional high schools were noted; accessibility, openness and diversity of specialized classes; some "strong" schools managed to pull up more "weak" schools. Among the negative aspects of the association, the following are highlighted: the gap in continuity between various links: primary, secondary and senior; low psychological safety of participants in the educational process in educational complexes; the achievements of schoolchildren in different divisions of the educational complex and in different classes are uneven and can vary greatly; additional paid education for children is additionally costly for their parents; the possibility of undermining the psychosocial and age-related aspects of normal socialization and personal development of a student due to the heavy workload of academic subjects; disproportionate funding between the structural divisions of the complex; reduction of teacher rates; destruction of a unique director's corps (directors and his deputies within one school as an established team of professionals); loss of the individuality of the educational organization, established values and traditions; a preschool educational organization can become, as it were ,an "appendage" of the school; with a large number of children in the educational complex, the phenomenon of depersonalization can occur, students become a "gray mass" , etc. It is emphasized that not only economic and managerial efficiency is important, but also pedagogical. Education specialists need to take into account the existing shortcomings of already operating educational complexes in order, as a result, to achieve the goals and content of education, primarily for students.

APA, Harvard, Vancouver, ISO, and other styles

24

Sairenji, Tomoko, Sarah E. Stumbar, Nana Aisha Garba, Prasad Bhoite, Maria Syl de la Cruz, Chivon Stubbs, John Emerson, Dolapo Babalola, David Kelley, and Kelly M. Everard. "Moving Toward a Standardized National Family Medicine Subinternship Curriculum:." Family Medicine 52, no. 7 (June 30, 2020): 523–27. http://dx.doi.org/10.22454/fammed.2020.209444.

Full text

Abstract:

Background and Objectives: Although the subinternship (sub-I) is considered integral in many medical schools’ curricula, family medicine does not have standardized course recommendations. Given the variable nature of this clinical experience, this study investigated the potential role of a standardized sub-I curriculum in family medicine. Methods: Questions about sub-Is were created and data were gathered and analyzed as part of the 2019 Council of Academic Family Medicine’s (CAFM) Educational Research Alliance (CERA) survey of family medicine clerkship directors. The survey was distributed via email to 126 US and 16 Canadian recipients between June 19, 2019 and August 2, 2019 through the online program SurveyMonkey. Results: A total of 101 (71.1%) of 142 clerkship directors responded to the survey. Most (84.2%) schools require sub-Is. There was a positive association between students matching into family medicine and having family medicine sub-Is at residency programs (P<.001). There was no relationship between higher family medicine match rates and the presence of family medicine sub-Is at nonresidency sites (P=.48) or having an advanced ambulatory rotation requirement (P=.16). Conclusions: A sub-I is a way to further expose students to family medicine, and increasing sub-I positions at residency programs may influence the number who pursue the specialty. Creation of a standardized sub-I curriculum presents an opportunity to enhance a critical educational experience in family medicine.

APA, Harvard, Vancouver, ISO, and other styles

25

Stinnett, Brad, and Fred Gibson. "Sustainable facility development: perceived benefits and challenges." International Journal of Sustainability in Higher Education 17, no. 5 (September 5, 2016): 601–12. http://dx.doi.org/10.1108/ijshe-09-2014-0133.

Full text

Abstract:

Purpose The purpose of this paper is to assess the perceived benefits and challenges of implementing sustainable initiatives in collegiate recreational sports facilities. Additionally, this paper intends to contribute to the evolving field of facility sustainability in higher education. Design/methodology/approach The design included qualitative research methods that allowed respondents to elaborate on perceived benefits and challenges. Respondents consisted of directors of campus recreation departments at National Intramural-Recreational Sports Association member institutions. Content analysis served as the method for analyzing and categorizing the data. Findings Six categories of perceived benefits became distinguishable, including Educational, Environmental, Ethical, Fiscal and Operational. Eight categories of perceived challenges emerged after responses were analyzed, including Administrative, Attitudinal, Commitment, Educational, Facility, and Fiscal. The majority of respondents indicated Fiscal demands as being the top challenge when it comes to implementing sustainable initiatives. Common themes arose from the responses and were sorted within their respective category. Originality/value This paper contributes to the evolving field of sustainability by providing some data regarding recreational sports facilities in higher education. Administrators, particularly those in Student Affairs, Facilities Management and Campus Recreation can benefit from this paper by assessing their respective institution’s current view of sustainability and by proactively determining a strategy to combat the potential challenges identified. Additionally, identifying perceived benefits can help equip facility directors and executives with justification and rationale for moving toward sustainable facility design and operation.

APA, Harvard, Vancouver, ISO, and other styles

26

Plake, Barbara S., Virginia Murphy-Berman, Linda E. Derscheid, Ruth Wenzl Gerber, Sherral K. Miller, Carol A. Speth, and Ruth E. Tomes. "Access Decisions by Personnel Directors: Subtle Forms of Sex Bias in Hiring." Psychology of Women Quarterly 11, no. 2 (June 1987): 255–64. http://dx.doi.org/10.1111/j.1471-6402.1987.tb00788.x.

Full text

Abstract:

Midwestern personnel and management association members rated bogus job applications which had identical background qualifications but varied by sex of applicant, sex-role related attributes of applicant, and degree of fit of applicant credentials to job demands. The applicants were rated on their qualifications and likelihood of being considered for the position, expected performance, and expected success in the job. A significant triple interaction was found for the variable that measured the likelihood of the applicant being considered for the position (i.e., access to the position). Higher access ratings were given to the sex—stereotypical applicant when the applicant's credentials matched job demands. When the applicant's credentials did not fit the job demands, raters tended to favor non-stereotypical applicants. Practical and research implications are discussed.

APA, Harvard, Vancouver, ISO, and other styles

27

Widialvanti, Auliarahma, and Bernadia Linggar Yekti Nugraheni. "The Influence of Director Characteristics and Company Performances Towards Firm Value." Journal of Management and Business Environment (JMBE) 1, no. 1 (July 15, 2024): 86–107. http://dx.doi.org/10.24167/jmbe.v1i1.12034.

Full text

Abstract:

This study aims to investigate the influence of director characteristics and company performance towards firm value. There’s a lack of studies about how female director characteristics and company performance affect firm value in Indonesia, therefore this study combined measurements of director characteristics and company performance towards firm value. Using a sample of manufacturing firms listed on the Indonesia Stock Exchange (IDX) from 2018 to 2022, this study applies multiple regression to examine the potential positive associations between director characteristics, company performance, and firm value. Director characteristics are measured by two proxies: the representation of female directors and female educational background, while company performances are assessed by return on assets (ROA) and leverage. Firm value as a dependent variable is represented by Tobin’s Q. The findings indicate a positive association between return on assets and leverage to firm value. However, no evidence is found to support the influence of female representation and educational background towards firm value. Keywords: female_directors, education_background, female_representation, firm_performance, Tobin’s_Q

APA, Harvard, Vancouver, ISO, and other styles

28

Sellick, Clive. "Can child and family social work research really assist practice?" Children Australia 24, no. 4 (1999): 93–96. http://dx.doi.org/10.1017/s1035077200009445.

Full text

Abstract:

British social workers at the sharp end of foster care and social work practice have experienced a flood of official reports in recent years (Association of Directors of Social Services, 1997; Utting, 1997; Warren, 1997), mostly, though not exclusively, highlighting the problems of too few placements for an increasingly challenging number of children and young people. In addition, British and North American foster care research over the past twenty years has shown how children in public, including foster, care have been:

APA, Harvard, Vancouver, ISO, and other styles

29

Azibeiro Melchor, Raúl, Alberto Hernández Sánchez, Teresa González, Marta Sobas, Javier Martinez Elicegui, Angela Villaverde Ramiro, Axel Benner, et al. "Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database." Blood 138, Supplement 1 (November 5, 2021): 608. http://dx.doi.org/10.1182/blood-2021-150766.

Full text

Abstract:

Abstract Background: The development of new genetic profiling techniques such as Next Generation Sequencing (NGS) have helped to unravel the genomic landscape of a large number of hematological diseases. In acute myeloblastic leukemia (AML), many mutations have been found at diagnosis or during the course of the disease, either alone or in combination. Nevertheless, the clinical significance of most of them has not been well established. That is particularly true regarding infrequent gene mutations and their co-mutations as they are underrepresented in most case series that have been analyzed so far. The big data platform of HARMONY alliance provides the excellent basis for addressing this problem as it assimilates clinical and genomic information about AML patients from over 100 organisations in 18 European countries comprising more than 5000 patients. Anonymised and harmonized using OMOP standards, data collected in HARMONY are optimal for studying the impact of gene-gene-interactions overcoming differences related to data providers. Aims: To identify clinically significant genetic patterns of 2 or more concurrent mutations using the Harmony alliance AML database Methods: From the HARMONY alliance database, we selected ~3600 AML patients with NGS molecular panel analysis. We first performed survival analysis between each gene combination and then we rendered those with statistically significant differences in one easy-to-read graph using the Gephi platform (Fig. A). We then highlighted promising or unexpected associations and analyzed them one by one in greater detail. Finally, these results were validated on an independent cohort. Results: We found that the co-mutation of RAD21 (RAD21mut) in DNMT3A mutated (DNMT3Amut) AML impacted outcome compared to DNMT3Amut alone patients (Fig. B, 3-year survival, 81% vs 52%, p=0.016). However, this effect was exclusively seen in allogeneic transplant recipients. In order to identify possible bias that could be generated if RAD21mut were associated with other well-known favorable prognosis mutations, we compared the frequency of each mutation in our DNMT3Amut / RAD21mut subgroup with the global AML cohort. NPM1 co-mutation was more frequent in the DNMT3Amut / RAD21mut group (Fig. C 3, 84% of patients with NPM1 mutation (NPM1mut) vs 26% in the global cohort), potentially explaining the higher survival. Next, we tried to isolate the positive effect of NPM1 on outcome by comparing DNMT3Amut / NPM1mut patients with and without the RAD21 co-mutation. This analysis showed a favorable outcome only in RAD21mut patients compared to RAD21 wildtype (Fig. D, 3-year survival, 83% in RAD21mut / DNMT3Amut / NPM1mut vs 50% in DNMT3Amut / NPM1mut with RAD21 wildtype, p=0.016), one more time only in allogeneic transplant recipients. Finally in order to validate our results we reproduced this study from the beginning using an independent cohort of 3125 AML patients. The Gephi graph confirmed an association of DNMT3Amut / RAD21mut patients with better survival over DNMT3A alone (3 year-survival, 75% vs 37%, p<0.001). NPM1 co-mutation was again more frequent in the good prognosis group (76% vs 27%) but comparing RAD21mut / DNMT3Amut / NPM1mut patients with DNMT3Amut / NPM1mut alone still revealed good prognosis to be related with RAD21mut (3 year-survival, 87.5% in patients with RAD21mut vs 38% with RAD21 wildtype, p<0.001). Conclusions: Using the HARMONY alliance database we tested for potential gene co-mutations in AML patients, often very infrequently represented in other studies. Our data suggest that RAD21mut has a positive effect on outcome in patients receiving an allogeneic transplant with concurrent mutation of DNMT3A and NPM1. Even though NPM1mut is much more frequent in the DNMT3Amut / RAD21mut group, its association with favourable outcome seems to depend on the presence of an additional RAD21mut Keywords: AML , gene combinations, RAD21, DNMT3A, NPM1, HARMONY, big data. Figure: Graphical results. A. View obtained from the Gephi platform with the gene combinations and their effect on survival. B. Survival curves respectively of the DNMT3A+RAD21 cohort and the DNMT3A-only one. 1. Representation of the proportions of each mutation in the overall cohort (red) compared to the DNMT3A+RAD21 cohort (blue). D. Survival curves respectively of the NPM1+DNMT3A+RAD21 cohort and the NPM1+DNMT3A one. Figure 1 Figure 1. Disclosures Sobas: Novartis: Consultancy, Honoraria; Celgene: Consultancy, Honoraria. Heckman: Novartis: Research Funding; Orion Pharma: Research Funding; Celgene/BMS: Research Funding; Oncopeptides: Consultancy, Research Funding; Kronos Bio, Inc.: Research Funding. Ayala: Incyte Corporation: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria; Celgene: Honoraria. Dombret: Amgen: Honoraria, Research Funding; Incyte: Honoraria, Research Funding; Jazz Pharmaceuticals: Honoraria, Research Funding; Novartis: Research Funding; Pfizer: Honoraria, Research Funding; Servier: Research Funding; Abbvie: Honoraria; Daiichi Sankyo: Honoraria; BMS-Celgene: Honoraria. Sierra: Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz Pharmaceuticals: Research Funding; Novartis: Honoraria, Research Funding, Speakers Bureau; BMS Celgene: Honoraria, Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Honoraria; Roche: Other: Educational grant; Janssen: Other: Educational grant; Amgen: Other: Educational grant; Alexion: Other: Educational grant. Mayer: Principia: Research Funding. Voso: Celgene: Consultancy, Research Funding, Speakers Bureau; Novartis: Speakers Bureau. Sanz: Helsinn Healthcare: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Boehringer Ingelheim: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, and expenses; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, and expenses, Speakers Bureau; Gilead Sciences: Other: Travel, accommodations, and expenses; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, and expenses, Research Funding. Calado: Novartis: Current Employment. Döhner: Janssen: Honoraria, Other: Advisory Board; Jazz Roche: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Astellas: Research Funding; Agios and Astex: Research Funding; Daiichi Sankyo: Honoraria, Other: Advisory Board; Celgene/BMS: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Gaidzik: Janssen: Speakers Bureau; Pfizer: Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Heuser: AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Research Funding; BergenBio: Research Funding; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees, Research Funding; Tolremo: Membership on an entity's Board of Directors or advisory committees; Astellas: Research Funding; Bayer Pharma AG: Research Funding. Haferlach: MLL Munich Leukemia Laboratory: Other: Part ownership. Turki: Jazz Pharma: Consultancy, Speakers Bureau; MSD: Consultancy, Speakers Bureau; CSL Behring: Consultancy. Schulze-Rath: Bayer: Current Employment. Hernández Rivas: Celgene/BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees. Bullinger: Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Hexal: Consultancy; Gilead: Consultancy; Abbvie: Consultancy, Honoraria; Menarini: Consultancy; Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Amgen: Honoraria; Astellas: Honoraria; Sanofi: Honoraria; Seattle Genetics: Honoraria; Bayer: Research Funding. Döhner: Jazz: Honoraria, Research Funding; Janssen: Honoraria; GEMoaB: Honoraria; Astellas: Honoraria, Research Funding; Astex: Honoraria; Agios: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Roche: Honoraria; Pfizer: Research Funding; Novartis: Honoraria, Research Funding; Oxford Biomedicals: Honoraria; Helsinn: Honoraria; BMS: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; AstraZeneca: Honoraria; Berlin-Chemie: Honoraria; Amgen: Honoraria, Research Funding. Ossenkoppele: Servier: Consultancy, Honoraria; Agios: Consultancy, Honoraria; Abbvie, AGIOS, BMS/Celgene Astellas,AMGEN, Gilead,Servier,JAZZ,Servier Novartis: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Gilead: Consultancy, Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

30

Mazerolle, Stephanie M., Thomas G. Bowman, and William A. Pitney. "Multistakeholder Perspectives on the Transition to a Graduate-Level Athletic Training Educational Model." Journal of Athletic Training 50, no. 9 (September 1, 2015): 964–76. http://dx.doi.org/10.4085/1062-6050-50.7.08.

Full text

Abstract:

Context The decision has been made to move away from the traditional bachelor's degree professional program to a master's degree professional program. Little is known about the perceptions about this transition from those involved with education. Objective To examine multiple stakeholders' perspectives within athletic training education on the effect that a change to graduate-level education could have on the profession and the educational and professional development of the athletic trainer. Design Qualitative study. Setting Web-based survey. Patients or Other Participants A total of 18 athletic training students (6 men, 12 women; age = 24 ± 5 years), 17 athletic training faculty (6 men, 9 women, 2 unspecified; 7 program directors, 5 faculty members, 3 clinical coordinators, 2 unidentified; age = 45 ± 8 years), and 15 preceptors (7 men, 7 women, 1 unspecified; age = 34 ± 7 years) completed the study. Data Collection and Analysis Participants completed a structured Web-based questionnaire. Each cohort responded to questions matching their roles within an athletic training program. Data were analyzed following a general inductive process. Member checks, multiple-analyst triangulation, and peer review established credibility. Results Thirty-one (62%) participants supported the transition, 14 (28%) were opposed, and 5 (10%) were neutral or undecided. Advantages of and support for transitioning and disadvantages of and against transitioning emerged. The first higher-order theme, advantages, revealed 4 benefits: (1) alignment of athletic training with other health care professions, (2) advanced coursework and curriculum delivery, (3) improved student and professional retention, and (4) student maturity. The second higher-order theme, disadvantages, was defined by 3 factors: (1) limited time for autonomous practice, (2) financial concerns, and (3) lack of evidence for the transition. Conclusions Athletic training students, faculty, and preceptors demonstrated moderate support for a transition to the graduate-level model. Factors supporting the move were comparable with those detailed in a recent document on professional education in athletic training presented to the National Athletic Trainers' Association Board of Directors. The concerns about and reasons against a move have been discussed by those in the profession.

APA, Harvard, Vancouver, ISO, and other styles

31

Ciesielkiewicz, Monika. "Education for employability: the ePortfolio from school principals’ perspective." On the Horizon 27, no. 1 (March 11, 2019): 46–56. http://dx.doi.org/10.1108/oth-01-2019-0001.

Full text

Abstract:

Purpose The purpose of this paper is to explore the question of whether the school principals would use an educational ePortfolio for recruiting purposes. Design/methodology/approach To examine whether the school principals are willing to use the educational ePortfolio for recruiting purposes, a survey was carried out among 35 school principals. The final version of the survey was audited by a panel of four experts on education and instructional technology, and a board member of the Spanish Association of Human Resources Directors (AEDRH) to ensure the clarity, relevance and validity of the items in the survey. Findings The information collected from this study provides a better understanding of the perception and approval rating of ePortfolios as a job search tool in the education sector. The research findings reveal that an educational ePortfolio can count with a significant approval among school principals in the Spanish context. The insight gained from this study might encourage leaders of educational institutions to adapt ePortfolios and foster their implementation into curriculum as a part of the higher education system. Originality/value This study is relevant and contributes to advancing knowledge in the field as it is the only research on this topic, up to now, conducted in the context of Spanish-speaking countries.

APA, Harvard, Vancouver, ISO, and other styles

32

Broudy, Virginia C., and Scot G. Hickman. "Teaching Hematology to Second Year Medical Students: Results of a National Survey of Hematology Course Directors." Blood 108, no. 11 (November 16, 2006): 3300. http://dx.doi.org/10.1182/blood.v108.11.3300.3300.

Full text

Abstract:

An Association of American Medical Colleges position paper calls for a 30% increase in medical school enrollment by 2015. New faculty effort certification reporting requirements for NIH-supported investigators and increasing clinical productivity expectations at academic medical centers challenge the tradition of faculty volunteerism for medical student teaching. To better define the structure, content, and financial support of second year medical school hematology courses nationwide, in 2001/2002 we mailed a survey to the hematology course directors at 85 of the 125 accredited US medical schools. The 58 course directors who returned the survey represent all regions of the US, and both public and private medical schools. Ten of the hematology course directors subspecialized in areas other than adult or pediatric hematology or hematology/oncology. Median class size was 150 students (range 40–200), and some courses included a substantial proportion (up to 33%) of students other than medical students (dental students, graduate students, PA students). Median course hours was 33 hours (range 8 to 74, an almost 10-fold difference). Approximately 50% of the total teaching time was devoted to lecture (range 5% to 100%), but a wide variety of additional teaching approaches were also employed, including small group discussions, problem-based learning, and web-based teaching (used by 62% of course directors). The median number of faculty responsible for teaching the second year hematology course was 12 (range 1–36). The hematology course directors identified a number of obstacles, including difficulty recruiting teachers (experienced by 45% of course directors), the lack of well-defined content, and the very modest budget (less than $1500 for most courses). Only 3 of the course directors indicated that they received salary support for this role. The findings of this survey suggest that a national effort to define learning objectives for the hematology courses and to share teaching materials among medical schools is warranted. Of note, it was estimated in 1997 that the total educational costs for one medical student are $72,000–92,000 per year, and that the majority of these costs are instructional. In 2003 median medical school tuition nationally was $16,322 (for a state resident attending a public school) and $34,550 (private school tuition). The present results show that few of these funds are directed to support of faculty time to teach the hematology course, and compel the identification of a funding stream to pay faculty for teaching medical student required courses.

APA, Harvard, Vancouver, ISO, and other styles

33

Grupp, Stephan, Zhen-Huan Hu, Yiyun Zhang, Amy Keating, Michael A. Pulsipher, Christine Philips, Steven P. Margossian, et al. "Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry." Blood 134, Supplement_1 (November 13, 2019): 2619. http://dx.doi.org/10.1182/blood-2019-129279.

Full text

Abstract:

Background Tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immunotherapy approved for the treatment of patients up to 25 years of age with B-cell ALL that is refractory or in second or later relapse. In the pivotal ELIANA trial, 79 patients were treated with tisagenlecleucel. The best overall response rate (CR/CRi) was 82%; 98% of patients who achieved CR/CRi were also negative for minimal residual disease (MRD). With a median follow-up of 24 months, the median duration of remission was not reached. Grade 3 or higher cytokine release syndrome (CRS) by UPenn criteria and neurotoxicity within the first 8 weeks after infusion occurred in 49% and 13%, respectively (Grupp, et al. Blood 2018, Abstr 895). The CIBMTR CT Registry was developed to collect long-term safety and efficacy information on recipients of cellular immunotherapies and it is utilized for a post marketing study of tisagenlecleucel in the real world setting. Methods Clinical data from the CT registry were analyzed for baseline information. Efficacy and safety data were presented among patients with a minimum of 3 months follow-up. CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were reported as per the ASTCT consensus criteria. Additionally, manufacturing product characteristics of tisagenlecleucel were compared to clinical outcomes. The association of number of cells administered, cell viability, potency, and transduction efficiency of tisagenlecleucel to overall response, CRS and ICANS grades was performed using descriptive summaries and univariate logistic regression analyses. Results Forty centers in the U.S. contributed data for refractory or relapsed pediatric or young adult patients with B-cell ALL through the CIBMTR CT registry as of May 31, 2019. Baseline information was available for 159 patients; 105 patients had at least the first follow up assessment reported at 3 months (Table 1). The median follow-up of survivors was 5.8 months (2.6-16.9 months). All patients received cells in the approved range for their weight with a median of 1.9 x 106/kg (range 0.2-4.6 x 106/kg) for children ≤ 50 kg and 0.9 x 108 (range 0.1-2.3 x 108) for children and young adults > 50 kg. The best overall response rate (CR) was 88% (95% CI 80%-94%). MRD was collected in 52 patients after tisagenlecleucel; all were negative. Importantly, among the 4 patients age < 3 years of age with more than 3 months of follow-up, all attained a CR. The 6-month duration of response, event-free survival and overall survival (OS) was 77%, 68% and 94%, respectively. After bridging therapy, there were 35 patients who attained CR and 63 patients who did not attain CR at the time of tisagenlecleucel infusion. The 6-month OS rate was 100% and 90.2% for patients attaining CR and not attaining CR, respectively. The rate of grade 3 or higher CRS and ICANS was 13.3% and 8.6%, respectively and was similar for patients age < 3 years. Clinically significant infections within the first 3 months occurred in 35.2% of patients; bacterial infections were most common. Deaths within 30 days following infusion occurred in 2 patients (due to disease progression and cerebral hemorrhage) and no deaths were attributed directly to tisagenlecleucel. Secondary malignancy was reported in 1 patient (myeloproliferative neoplasm). None of the manufacturing characteristics (cell viability, potency, nor transduction efficiency) or cell dose were associated with efficacy or safety. Importantly, analysis of cell viability showed no association with best overall response (Table 2). Conclusions The CIBMTR CT registry represents real world data for the treatment of pediatric patients with relapsed/refractory ALL and will allow follow up of these patients for 15 years. Tisagenlecleucel therapy in the real world setting demonstrated similar efficacy and safety compared to the pivotal ELIANA trial. None of the manufacturing characteristics analyzed (including % cell viability) correlated with response rates, CRS or ICANS. Updated results will be presented at the meeting. Disclosures Grupp: CBMG: Consultancy; Novartis: Research Funding; Kite: Research Funding; Servier: Research Funding; Novartis: Consultancy, Research Funding; Roche: Consultancy; GSK: Consultancy; Cure Genetics: Consultancy; Humanigen: Consultancy; Jazz: Other: study steering committees or scientific advisory boards; Adaptimmune: Other: study steering committees or scientific advisory boards. Pulsipher:Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz: Other: Education for employees; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; CSL Behring: Membership on an entity's Board of Directors or advisory committees; Amgen: Other: Lecture; Bellicum: Consultancy; Miltenyi: Research Funding; Medac: Honoraria. Margossian:Novartis: Membership on an entity's Board of Directors or advisory committees. Curran:Novartis: Consultancy; Juno Therapeutics: Consultancy, Research Funding. Nikiforow:Kite/Gilead: Honoraria; Novartis: Honoraria; NKarta: Honoraria. Chawla:Novartis Pharma AG: Employment. Horowitz:Actinium: Other: Unrestricted educational and research grant; Mesoblast: Other: Unrestricted educational and research grant, Research Funding; CSL Behring: Other: Unrestricted educational and research grant, Research Funding; Daiichi Sankyo: Other: Unrestricted educational and research grant; Magenta: Consultancy, Other: Unrestricted educational and research grant; GlaxoSmithKline: Other: Unrestricted educational and research grant; Miltenyi Biotech: Other: Unrestricted educational and research grant, Research Funding; Bristol-Myers Squibb: Other: Unrestricted educational and research grant, Research Funding; Oncoimmune: Other: Unrestricted educational and research grant; Chimerix: Other: Unrestricted educational and research grant; Amgen: Other: Unrestricted educational and research grant; Shire: Other: Unrestricted educational and research grant; Gamida Cell: Other: Unrestricted educational and research grant, Research Funding; Janssen: Other: Unrestricted educational and research grant, Research Funding; Kite Pharma/Gilead: Other: Unrestricted educational and research grant, Research Funding; Pharmacyclics: Other: Unrestricted educational and research grant; Regeneron: Other: Unrestricted educational and research grant; Sanofi: Other: Unrestricted educational and research grant, Research Funding; Seattle Genetics: Other: Unrestricted educational and research grant. Bleickardt:Novartis: Employment. Pasquini:Novartis: Research Funding; Kit Pharma: Research Funding; BMS: Research Funding; Pfizer: Other: Advisory Board; Amgen: Consultancy; Medigene: Consultancy.

APA, Harvard, Vancouver, ISO, and other styles

34

Sukholentseva, E. N. "PEDAGOGICAL COUNSELING OF ADOLESCENTS AT RISK IN A PUBLIC ASSOCIATION DURING THE COVID-19 PANDEMIC." Pedagogical IMAGE 14, no. 4 (2020): 556–67. http://dx.doi.org/10.32343/2409-5052-2020-14-4-556-567.

Full text

Abstract:

Abstract. The paper presents a perspective on pedagogical counseling for adolescents at risk in a children’s public association during the COVID-19 pandemic. The directions of pedagogical counseling of adolescents at risk are described with their focus on social responsibility, responsible attitude to their future, the future of our country, and the nation’s health during the COVID-19 pandemic. The paper shows the experience of implementing the system of pedagogical counseling for adolescents at risk in a public association during the coronavirus pandemic. It also presents the findings of an empirical study on the formation of social responsibility in adolescents at risk during the COVID-19 pandemic. Materials and methods. The study employed retrospective and comparative types of analysis of scientific sources, testing of adolescents at risk, content-analysis of documents of public associations and educational organizations, and analysis of the public associations’ experience. Research results. The study identifies the methodological framework of counseling for adolescents at risk in a public association, describes the experience of implementing the pedagogical counseling for adolescents at risk and members of a public association during the coronavirus pandemic. The scientific novelty of this study lies in the transformability of the pedagogical counseling system from an offline to an online format. This system allows working with children both in direct contact and in a distant way. Conclusion. The findings made it possible to put into practice the online system of pedagogical counseling for adolescents at risk, which emphasizes a responsible attitude to their future, the future of our country, and the national health. The research materials can be useful to counselors, organizers, educators, psychologists, deputy directors of educational organizations, students, scientific and pedagogical community. Keywords: COVID-19 pandemic, coronavirus, pedagogical counseling, adolescents at risk, public associations.

APA, Harvard, Vancouver, ISO, and other styles

35

Bouchefra, Said, Amal Azeroual, Hassan Boudassamout, Khalid Ahaji, Abdelhakim Ech-chaouy, and Abdellatif Bour. "Association between Non-Verbal Intelligence and Academic Performance of Schoolchildren from Taza, Eastern Morocco." Journal of Intelligence 10, no. 3 (August 19, 2022): 60. http://dx.doi.org/10.3390/jintelligence10030060.

Full text

Abstract:

Interest in identifying factors influencing educational success is growing. It is often observed that a group of students share the same external variables (school environment) yet have different results, which states that individual variables have more impact on the determination of academic performance. Therefore, the present study aimed to substantiate this fact by investigating the association between non-verbal fluid intelligence and academic performance in a population of schoolchildren in Eastern Morocco. The investigation was a cross-sectional study based on a self-administered questionnaire. Items included the standard Raven’s progressive matrices. Students’ grades were collected from the administrative offices of the visited schools. Significant and positive correlations between the non-verbal intelligence scores and the school results were found: for the general average, the correlation was 0.574; for the school subject French, the correlation coefficient was 0.475; and for mathematics, we found a relatively low coefficient of 0.381. Non-verbal fluid intelligence significantly and positively predicted academic performance (β = .574, p = .000). These results call for policymakers to implement the use of intelligence tests with school directors and teachers as a diagnostic tool to guide support efforts for low-achieving children and even to create pilot classes for the best-performing students.

APA, Harvard, Vancouver, ISO, and other styles

36

El Rassi, Fuad, John James, Biree Andemariam, Beverley Francis-Gibson, Caterina P. Minniti, Jincy Paulose, Tom Bailey, Olivera Rajkovic-Hooley, and Ifeyinwa Osunkwo. "Children in the United States with Sickle Cell Disease Experience Greater Educational Burden Than Those Living in Low/Middle Income and Other High-Income Countries." Blood 138, Supplement 1 (November 5, 2021): 3106. http://dx.doi.org/10.1182/blood-2021-146566.

Full text

Abstract:

Abstract Introduction: The Sickle Cell World Assessment Survey (SWAY) was a cross-sectional survey to assess the global impact and treatment of sickle cell disease (SCD). Complications of SCD can lead to significant negative effects on patient (pt) quality of life. Recurrent vaso-occlusive crises (VOCs) are one of the most common SCD complications and can lead to poor quality of life and chronic organ damage. SCD manifestations can start as early as the first year of life. The implications of SCD on a child's life can be far reaching and may affect education, the global impact of which has not been well described. Here, we assess data from SWAY to better understand the impact of SCD on education among pediatric pts in the US vs other high-income countries (HIC) and low/middle-income countries (LMIC). Methods: SWAY included individuals aged ≥6 years with a diagnosis of SCD. The survey was completed by proxy (parent/caregiver/guardian) for pts aged 6-11 years and could be optionally self-completed by pts aged ≥12 years. The survey consisted of 7 ratings-based (Likert scale) questions focused on education, where a score of 5, 6, or 7 indicated increasing levels of agreement. Pediatric pts were defined as those aged <18 years. Per the World Bank definition, HIC were defined as having a gross national income per capita of ≥US$12,536; LMIC represented all remaining countries. SWAY was not designed to assess treatment outcomes; all analyses are descriptive. Age groups were not matched, and pts were not followed up over time. Results: Among the 769 pediatric pts participating in SWAY, there were 77 US respondents to the educational survey (mean age, 12 y), 200 HIC respondents (mean age, 13 y), and 492 LMIC respondents (mean age, 12 y, [one respondent did not provide an age]). Pediatric pts in all groups reported that SCD adversely impacted their education. Of the US respondents, 51%, 45%, and 52% agreed that SCD negatively impacted performance on school tests, overall performance at school, and school attendance, respectively. This was a higher rate of agreement for these statements than that reported by pediatric pts from other HIC (25%, 23%, 36%) and LMIC (37%, 41%, 50%). The US respondents also agreed that SCD negatively affected performance on homework (45%), caused them to repeat a year or class (42%), lowered interest in school (36%), and limited educational progression (35%). Again, this was a higher rate of agreement than that reported by pediatric pts from other HIC (26%, 14%, 19%, 20%) and LMIC (37%, 32%, 34%, 29%). Interestingly, the largest differences in reported school impact occurred between the US and HIC, where the US respondents showed nearly two-fold higher agreement for all statements except for reduced attendance. Conversely, there were only minor differences between respondents from the US and LMIC. Full results are presented in the Figure. Conclusions: A higher proportion of pediatric pts in the US reported a negative impact of SCD on schooling compared with those in HIC and LMIC. These results were unexpected but align strongly with the emerging evidence that social determinants prevalent in the US lends itself away from the benefits of living in a resource-rich nation. Figure 1 Figure 1. Disclosures James: GBT: Honoraria; Novartis: Honoraria. Francis-Gibson: Global Alliance of SCD Organizations: Membership on an entity's Board of Directors or advisory committees; Sickle Cell Disease Association of America: Current Employment; Alliance for Regenerative Medicine Foundation for Cell and Gene Medicine: Membership on an entity's Board of Directors or advisory committees; ASH: Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees. Minniti: GBT: Consultancy, Research Funding; Novartis: Consultancy, Honoraria; NovoNordisk: Consultancy, Honoraria; Roche: Consultancy, Honoraria. Paulose: Novartis Pharmaceuticals Corporation: Current Employment. Bailey: Novartis Pharmaceuticals: Other: I am an employee of Adelphi Real World, which received payment from Novartis Pharmaceuticals for this research. Rajkovic-Hooley: Novartis Pharmaceuticals: Other: I am an employee of Adelphi Real World, which received payment from Novartis Pharmaceuticals for this research. Osunkwo: Forma Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Health and Services Administration: Research Funding; Patient Centered Outcomes Research Instituted: Research Funding; Micella Biopharma: Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Chiesi: Consultancy; Emmaus: Consultancy; Cyclerion: Consultancy; Acceleron: Consultancy; Global Blood Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Terumo: Consultancy.

APA, Harvard, Vancouver, ISO, and other styles

37

Matteuzzi, Tommaso, Daniele Dall'Olio, Eric Sträng, Alessandra Merlotti, Javier Martinez Elicegui, Axel Benner, Maral Saadati, et al. "Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study." Blood 138, Supplement 1 (November 5, 2021): 3438. http://dx.doi.org/10.1182/blood-2021-152215.

Full text

Abstract:

Abstract The large acute myeloid leukemia (AML) patient-derived data sets collected within the European HARMONY alliance allows to study the molecular heterogeneity underlying AML in detail. Especially, how cytogenetic and molecular genetic aberrations differentially affect patients. Here, we report first results on the differences in mutational patterns in males and females. We studied a cohort of AML patients characterized by a panel of 70 molecular abnormalities comprising both cytogenetic and genetic observations. We quantified the differences of molecular patterns between sexes in two ways: 1) by comparing the number of gene-gene mutation co-occurrence and mutual mutation exclusivity with a χ 2 test, 2) exploiting the Hierarchical Dirichlet process (HDP) for molecular components discovery. In particular, we added sex as a further layer of the hierarchy allowing the same molecular components to be differently re-weighted based on gender. The HARMONY AML cohort comprised 2796 patients with detailed molecular information from targeted sequencing of 41 genes and detailed cytogenetic information condensed into 29 cytogenetic properties, known, a priori, to be relevant for the disease. Male to female ratio was 52% vs. 48% and median age was 52.0 (18.2 - 91.4) years. The entry data of the analysis were in the form of a binary matrix reporting the presence/absence of a given alteration in a patient. The χ 2 test based on the relative co-occurrence of mutation pairs suggested a significant difference between men and women solely for RUNX1 and NPM1. The number of co-occurrences was higher in male than in females. No significant mutual exclusive mutations were found between the populations. By using a two hierarchic levels HDP clustering we identified 11 overall molecular components shared by all AML patients. Six of these components are characterized by one or more genetic drivers, namely: NPM1, RUNX1, Complex-Karyotype-TP53, FLT3-IDH2, IDH2, CEPBA-biallelic, while the others were driven by cytogenetic abnormalities: t(6;9), t(8;21), inv(3), rearrangement of 11q23, inv(16). These results were in agreement with the current WHO AML classification and with other recent studies, which have attempted to improve stratification/classification of patients based on their molecular aberration patterns. While the molecular components were the same for all patients, major differences were observed in the contribution of NPM1 and RUNX1 components to males' and females' genotypes. On one side, NPM1 component has a double weight in females with respect to males. On the other hand, RUNX1 impacts males much more than females. The other aberrations were equally represented in both sexes. To test the robustness of the differences found between sexes, we compared these results with random splits of the datasets finding no differences in component weights, thereby validating our observations. Big data collections such as the HARMONY Alliance data base ensure data comparability via OMOP common data model harmonization approaches thereby offering the possibility to study large cohort that allow meaningful subgroup analyses such as the one focusing on gender imbalances. Proving the concept of the HARMONY Alliance data hub, our study confirms a female preponderance for NPM1 mutations and an association of RUNX1 mutations with male gender. Impact on patient outcome is currently evaluated and will be presented at the annual meeting. Figure 1 Figure 1. Disclosures Heckman: Celgene/BMS: Research Funding; Orion Pharma: Research Funding; Novartis: Research Funding; Oncopeptides: Consultancy, Research Funding; Kronos Bio, Inc.: Research Funding. Dombret: Abbvie: Honoraria; Amgen: Honoraria, Research Funding; Incyte: Honoraria, Research Funding; Jazz Pharmaceuticals: Honoraria, Research Funding; NOVARTIS: Research Funding; pfizer: Honoraria, Research Funding; servier: Research Funding; BMS-Celgene: Honoraria; Daiichi Sankyo: Honoraria. Montesinos: Tolero Pharmaceutical: Consultancy; Agios: Consultancy; Stemline/Menarini: Consultancy; Teva: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Forma Therapeutics: Consultancy; Glycomimetics: Consultancy; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Astellas Pharma, Inc.: Consultancy, Honoraria, Other: Advisory board, Research Funding, Speakers Bureau. Sierra: Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Honoraria, Research Funding, Speakers Bureau; Jazz Pharmaceuticals: Research Funding; Janssen: Other: Educational grant; Roche: Other: Educational grant; Pfizer: Honoraria; BMS Celgene: Honoraria, Research Funding; Alexion: Other: Educational grant; Amgen: Other: Educational grant; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Mayer: Principia: Research Funding. Voso: Novartis: Speakers Bureau; Celgene: Consultancy, Research Funding, Speakers Bureau. Sanz: Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, and expenses; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, and expenses, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Boehringer Ingelheim: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead Sciences: Other: Travel, accommodations, and expenses; Helsinn Healthcare: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, and expenses, Research Funding. Calado: Novartis: Current Employment. Döhner: Agios and Astex: Research Funding; Daiichi Sankyo: Honoraria, Other: Advisory Board; Jazz Roche: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Janssen: Honoraria, Other: Advisory Board; Astellas: Research Funding; Celgene/BMS: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Gaidzik: Pfizer: Speakers Bureau; Janssen: Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Heuser: BergenBio: Research Funding; Jazz Pharmaceuticals: Honoraria, Research Funding; BMS/Celgene: Research Funding; Bayer AG: Honoraria, Research Funding; Astellas: Research Funding; Daichi Sankyo: Honoraria, Research Funding; Karyopharm: Research Funding; Novartis: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Roche: Research Funding; Tolremo: Honoraria; AbbVie: Honoraria; Janssen: Honoraria. Haferlach: MLL Munich Leukemia Laboratory: Other: Part ownership. Sobas: Celgene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Turki: CSL Behring: Consultancy; Jazz Pharma: Consultancy, Speakers Bureau; MSD: Consultancy, Speakers Bureau. Schulze-Rath: Bayer: Current Employment. Hernández Rivas: Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene/BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees. Döhner: Abbvie: Honoraria, Research Funding; Agios: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Astellas: Honoraria, Research Funding; Astex Pharmaceuticals: Honoraria; AstraZeneca: Honoraria; Berlin-Chemie: Honoraria; Bristol Myers Squibb: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; GEMoaB: Honoraria; Gilead: Honoraria; Helsinn: Honoraria; Janssen: Honoraria; Jazz Pharmaceuticals: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Oxford Biomedica: Honoraria; Pfizer: Research Funding; Roche: Honoraria. Ossenkoppele: Abbvie, AGIOS, BMS/Celgene Astellas,AMGEN, Gilead,Servier,JAZZ,Servier Novartis: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Agios: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; Gilead: Consultancy, Honoraria. Bullinger: Menarini: Consultancy; Amgen: Honoraria; Hexal: Consultancy; Novartis: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Astellas: Honoraria; Abbvie: Consultancy, Honoraria; Gilead: Consultancy; Sanofi: Honoraria; Seattle Genetics: Honoraria; Bayer: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

38

Grainger, John, James B. Bussel, Nichola Cooper, Michael Tarantino, Victor Blanchette, Jenny Despotovic, Alexey Maschan, Nancy Carpenter, Melissa Eisen, and Bhakti Mehta. "A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)." Blood 128, no. 22 (December 2, 2016): 869. http://dx.doi.org/10.1182/blood.v128.22.869.869.

Full text

Abstract:

Abstract Background: The TPO receptor agonist romiplostim is approved for use in adults with chronic ITP. The use of romiplostim in children with ITP has been evaluated in phase 1/2 and 3 studies. In this study, children with ITP will receive open-label SC romiplostim for up to 3 years (y). Methods: Eligible children, recruited in 16 countries worldwide, had ITP for ≥6 months, ≥1 prior ITP therapy, and platelet (plt) count ≤30×109/L. Weekly SC dosing started at 1 μg/kg and was titrated in 1 μg/kg increments up to 10 μg/kg to target plt counts of 50-200×109/L. In patients in Europe, bone marrow aspirates and biopsies were obtained at baseline and after 1 or 2 y of exposure. The 1º endpoint was the % of time in the first 6 months with a plt response, with response defined as a plt count ≥50×109/L without rescue medication use in the past 4 weeks (wk). Results: As of 15 Mar 2016, 147 patients enrolled; 145 received ≥1 romiplostim dose. At baseline, median (min-max) age was 10 (2-17) y; 51% were female; 4% had prior splenectomy. Median (min-max) ITP duration was 1.9 (0.5-12.3) y and plt count was 13 (2-168)×109/L. The median (Q1, Q3) % of time with a plt response in the first 6 months patients were on study was 50% (0%, 83.3%); that of months 7-12 was 92% (33%, 100%). Over the course of the study, 80% (114/143) of patients had a plt response. The median (Q1, Q3) % of time with an increase in plt counts ≥20×109/L above baseline was 60% (25%, 84%). The median dose increased to 10 μg/kg by wk 32 (Figure). Median (min-max) treatment duration as of data cutoff was 25 (1-67) wk for a total exposure to date of 79 patient-years; 67 (46%) patients (or caregivers) self-administered romiplostim. Median (min-max) average weekly romiplostim dose was 6.1 (0.4-9.0) µg/kg. Thirty-two patients (22%) discontinued treatment for lack of efficacy (n = 17), required other therapy (n = 5), patient request (n = 4), noncompliance (n = 2), adverse event (AE) (n = 2) (interstitial lung disease unrelated to treatment in a 15 y old boy and abdominal pain, vomiting, and headache related to treatment per investigator in a 9 y old girl), administrative decision (n = 1), and investigator decision (n = 1). After wk 12, median plt counts remained ≥50×109/L (Figure). Thirty-four (23%) patients received rescue medications. The most frequently reported AEs were headache (27.6%), epistaxis (22.8%), and nasopharyngitis (23%); 15 (10.3%) patients had serious AEs (SAEs) including epistaxis (n = 4), petechiae (n = 2), decreased plt count (n = 2), and thrombocytopenia (n = 2). A case of abdominal pain was the only SAE deemed treatment-related by the investigator. Bleeding over the course of the study was seen in 52% of patients. CTCAE grade 3 bleeding was seen in 8 patients (6%) and included epistaxis (n = 5), ecchymosis (n = 2), petechiae (n = 2), and 1 case each of hematemesis, hematoma, SC hemorrhage, injection site hemorrhage, and mouth hemorrhage. No grade 4 or 5 bleeding was observed. One event of grade 2 phlebitis/thrombophlebitis in deep veins in the left arm lasting 14 days was reported in a 13 y old girl; plt counts were 40-70×109/L and the dose was 7-8 µg/kg during this time. Per investigator, this event was not serious or related to romiplostim. She was treated with antibiotics (oral amoxicillin/clavulanic acid and transdermal muciprocin) and continued romiplostim treatment as before. No neutralizing antibodies against romiplostim or TPO were identified. Of 30 patients with baseline bone marrow biopsies [50% female, median (min-max) age 10.5 (6-12) y, ITP duration 3.1 (0.6-11) y], all had modified Bauermeister scores of grade 0 (no reticulin) or 1 (fine fibers) and bone marrow typical for ITP. Of these 30 patients, 21 had evaluable on-study biopsies, with no increases in 2 or more grades, findings of collagen, or bone marrow abnormalities. Conclusion: In this year 1 datacut of an ongoing open-label study of romiplostim in children with ITP, the % of time in the first 6 months with a platelet response was 50%, with 80% of children having a platelet response at some point on study. The median romiplostim dose reached 10 μg/kg and there were no new safety signals. No effects of romiplostim were observed in the subset of patients with bone marrow biopsies. Future datacuts for year 2 and 3 in this study, the largest of romiplostim in children with ITP with 79 patient-years of exposure to date, will provide more information on platelet response, dose requirements, and safety. Disclosures Grainger: Baxter: Honoraria, Research Funding; Amgen Inc.: Honoraria; Novartis: Honoraria; GlaxoSmithKline: Honoraria. Bussel:Shionogi: Membership on an entity's Board of Directors or advisory committees; Symphogen: Membership on an entity's Board of Directors or advisory committees; Ligand: Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Boehringer Ingelheim: Research Funding; BiologicTx: Research Funding; Eisai: Membership on an entity's Board of Directors or advisory committees, Research Funding; Prophylix Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Rigel Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Protalex: Membership on an entity's Board of Directors or advisory committees, Research Funding; Physicians Education Resource: Speakers Bureau; Genzyme: Research Funding; UpToDate: Patents & Royalties; Momenta Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Immunomedics: Research Funding; Cangene: Research Funding; Sysmex: Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Cooper:UK ITP support association: Research Funding; National Organization for Rare Disorders: Research Funding; Imperial College BRC: Research Funding; Eisai: Consultancy, Honoraria, Other: Received honoraria for speaking at educational meetings; GlaxoSmithKline: Consultancy, Honoraria, Other: Received honoraria for speaking at educational meetings ; Amgen Inc.: Consultancy, Honoraria, Other: Received honoraria for speaking at educational meetings . Tarantino:Pfizer: Research Funding; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees, Research Funding; Grifols: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Biogen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Baxalta: Membership on an entity's Board of Directors or advisory committees. Blanchette:Baxter: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Data safety monitoring boards , Research Funding; Bayer Healthcare: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novo Nordisk: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Octapharma: Other: Data safety monitoring boards . Carpenter:Amgen Inc.: Employment, Equity Ownership. Eisen:Amgen Inc.: Employment, Equity Ownership. Mehta:Amgen Inc.: Employment, Equity Ownership.

APA, Harvard, Vancouver, ISO, and other styles

39

Martins, Tomás Sparano, June Alisson Westarb Cruz, Heitor Takashi Kato, Julio Adriano Reis, and Amir El-Kouba. "The Influence of the Miles and Snow strategic typology in the degree of market orientation in institutions of primary/secondary education in the State of Parana." Revista Ibero-Americana de Estratégia 7, no. 2 (May 26, 2009): 125–38. http://dx.doi.org/10.5585/ijsm.v7i2.1336.

Full text

Abstract:

This paper investigates the influence of a strategic typology in the performance of grade schools and high schools in the state of PR, taking into account the degree of market orientation. The model was developed based on two concepts: the strategic typology of Miles and Snow (1978) and market-orientation in the model of Kohli, Jaworski and Kumar (1993). To conduct this study, a cross-sectional survey was done. Data collection was conducted through a questionnaire sent to the directors of all 699 schools associated with SINEPE-PR (The Association for Privately Owned Educational Institutions in State of Paraná). A total of 153 cases were considered valid for the research. To analyze the data the H Kruskal-Wallis Test was used through the Minitab statistical software version 15. It was found that the typology is a strategic factor that influences the market orientation variables in analyzed industry

APA, Harvard, Vancouver, ISO, and other styles

40

Jaeger, Ulrich, Michael R. Bishop, Gilles Salles, Stephen J. Schuster, Richard T. Maziarz, Xia Han, Alexander Savchenko, et al. "Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial." Blood 136, Supplement 1 (November 5, 2020): 48–49. http://dx.doi.org/10.1182/blood-2020-137045.

Full text

Abstract:

Background: Tisagenlecleucel (tisa-cel; autologous anti-CD19 CAR-T cell therapy) has demonstrated durable responses and a manageable safety profile in adult pts with r/r DLBCL in the JULIET trial. Here we report updated efficacy results with a 40 month median follow-up and associations with baseline Myc overexpression in tumor and tumor microenvironment (TME) characteristics. Methods: JULIET is a global, phase 2 trial of tisa-cel in adult pts with r/r DLBCL. The relationship between Myc overexpression (Myc+: >40% by immunohistochemistry [IHC]), TME characteristics (including CD3+ T-cell infiltration, myeloid-derived suppressor cells [MDSCs], and LAG3 expression by fluorescent IHC) with efficacy outcomes (Month 3 [M3] response, duration of response [DOR], progression-free survival [PFS], and overall survival [OS]), and genomic mutation profile with M3 response were assessed. Results: As of February 20, 2020 (median follow-up of 40.3 mo), 115 pts received tisa-cel infusion. Among the 61 pts with a response, the relapse-free probability was 60.4% at 24 and 30 mo; median DOR was not reached (95% CI, 10-not estimable [NE]). Median OS among all 115 infused pts was 11.1 months (95% CI, 6.6-23.9). Survival probability at 12, 24, and 36 months was 48.2%, 40.4%, and 36.2%, respectively. Median OS of pts with CR (n=37) or PR (n=7) at M3 was not reached; 80% of CR pts had an OS benefit of 20 months or longer. No new safety signals were detected. Of the 23 pts with ongoing CR and B-cell count available, 11 had CD19+ B cells recovered back to normal after 1 year, with similar patterns observed for CD20+ and CD22+ B cells. Of 111 pts whose baseline archival tumor biopsies were tested for baseline Myc expression, 73 were Myc+ and 38 were Myc−. Baseline Myc− status was associated with improved outcomes compared with Myc+ pts, including longer median DOR (not reached vs 19 months [95% CI, 3.4-NE]), PFS (6.2 months [95% CI, 2.9-NE] vs 2.5 months [95% CI, 1.7-3.0]; Fig.1A), and OS (21 months [95% CI, 10-NE] vs 7.8 months [95% CI, 4.6-18]). In the TME analysis of baseline biopsy, lack or low frequency of tumor-infiltrating CD3+ T cells (cutoff of ≤3%; n=16) was associated with shorter median PFS (2.2 months [95% CI, 0.92-2.8] vs 4.2 months [95% CI, 2.6-21]; Fig.1B) and OS (7 months [95% CI, 1.8-12] vs 21 months [95% CI, 6.7-NE]) compared with pts with >3% CD3+ T cells (n=64). Interrogation of checkpoint molecule expression on tumor-infiltrating CD3+ cells revealed that pts with the highest frequency of LAG3+CD3+ cells out of entire CD3+ T cell population (cutoff of >20%; n=12) at baseline had decreased median PFS (2.1 [95% CI, 0.82-3.1] vs 4.2 months [95% CI, 2.4-21]) and OS (4.3 [95% CI, 2.7-10] vs 21 months [95% CI, 10-NE]) compared with pts with ≤20% LAG3+CD3+ T cells (n=68). No differences in baseline clinical characteristics were observed in subgroups by Myc, CD3+, and LAG3+CD3+ expression. Additionally, in a small dataset, pts with the highest frequency of CD11b+HLA-DR− cells that represent MDSC phenotype at baseline were enriched with nonresponders. In a survival tree analysis including infiltrating T cells, LAG3+ CD3+ cells, Myc, and LDH, pts with Myc− status and normal pre-infusion LDH levels (n=16) had longer PFS compared with normal LDH and Myc+, and pts with LDH 1- to 2-fold or >2-fold above the upper limit of normal, with the latter group having a poor PFS. Whole exome sequencing of 46 baseline tumor samples was performed. No significant association with response was observed in mutations at the single-gene level. The correlation between molecular subtypes and M3 response was also investigated. Samples grouped into newly identified DLBCL subtypes (Chapuy et al. Nat Med. 2018; Schmitz et al. N Engl J Med. 2018; Wright et al. Cancer Cell. 2020) did not reveal an association with response, although the small sample size may limit interpretation. Conclusions: Updated long-term data with 40 months median follow-up from the JULIET trial demonstrate sustained benefit in responding pts; in particular 80% of CR pts had a long-term OS (≥20 months). Taken together, the results suggest that Myc overexpression, or an unfavorable immunosuppressive TME with restricted T-cell response, may impact CAR-T cell efficacy in pts with DLBCL. Disclosures Jaeger: AbbVie: Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Gilead: Honoraria, Research Funding; BMS/Celgene: Consultancy, Honoraria, Research Funding; Karyopharm: Honoraria; CDR Life AG: Consultancy, Research Funding; Miltenyi: Consultancy, Honoraria; F. Hoffmann-La Roche: Honoraria, Research Funding. Bishop:Incyte: Honoraria, Speakers Bureau; CRSPPR Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Autolus: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS: Honoraria, Speakers Bureau. Salles:Autolus: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Other: Educational events; BMS: Honoraria; Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Novartis, Servier, AbbVie, Karyopharm, Kite, MorphoSys: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Roche, Janssen, Gilead, Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Epizyme: Consultancy, Honoraria. Schuster:Novartis, Genentech, Inc./ F. Hoffmann-La Roche: Research Funding; AlloGene, AstraZeneca, BeiGene, Genentech, Inc./ F. Hoffmann-La Roche, Juno/Celgene, Loxo Oncology, Nordic Nanovector, Novartis, Tessa Therapeutics: Consultancy, Honoraria. Maziarz:Incyte, Kite, BMS/Celgene, PACT Pharma, Orca BioSystems, and Omeros: Honoraria; Novartis and Juno: Research Funding; Novartis and Athersys: Other: DSMB participant; Novartis, Incyte, CRISPR Therapeutics, Artiva Biotherapeutics, and AlloVir: Consultancy; Athersys: Patents & Royalties. Han:Novartis Pharmaceuticals Corporation: Current Employment. Savchenko:Novartis Pharmaceuticals Corporation: Current Employment. Roscoe:Navigate BioPharma Services, Inc., a Novartis Subsidiary: Current Employment. Orlando:Novartis Institutes for BioMedical Research: Current Employment. Knoblock:Novartis Pharmaceuticals Corporation: Current Employment. Tiwari:Novartis: Current Employment. Bubuteishvili Pacaud:Novartis: Current Employment. Corradini:Daiichi Sankyo: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Other: Travel and accommodations paid by for; Gilead: Consultancy, Honoraria, Other: Travel and accommodations paid by for; Incyte: Consultancy; Janssen: Consultancy, Honoraria; Kite: Consultancy, Honoraria; KiowaKirin: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Travel and accommodations paid by for; F. Hoffman-La Roche Ltd: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Other; BMS: Other; AbbVie: Consultancy, Honoraria, Other: Travel and accommodations paid by for; Amgen: Consultancy, Honoraria, Other: Travel and accommodations paid by for.

APA, Harvard, Vancouver, ISO, and other styles

41

Weiss, Ronald L., Lewis A. Hassell, and Eric R. Parks. "Progress Toward Improved Leadership and Management Training in Pathology." Archives of Pathology & Laboratory Medicine 138, no. 4 (April 1, 2014): 492–97. http://dx.doi.org/10.5858/arpa.2013-0288-ra.

Full text

Abstract:

Context.—Competency gaps in leadership and laboratory management skills continue to exist between what training programs deliver and what recent graduates and future employers expect. A number of recent surveys substantiate this. Interest in delivering content in these areas is challenged by time constraints, the presence of knowledgeable faculty role models, and the necessary importance placed on diagnostic skills development, which overshadows any priority trainees have toward developing these skills. Objective.—To describe the problem, the near-future horizon, the current solutions, and the recommendations for improving resident training in laboratory management. Data Sources.—The demands of new health care delivery models and the value being placed on these skills by the Pathology Milestones and Next Accreditation System initiative of the Accreditation Council for Graduate Medical Education for training programs emphasizes their importance. This initiative includes 6 milestone competencies in laboratory management. Organizations like the American Society for Clinical Pathology, the American Pathology Foundation, the College of American Pathologists, and the Association of Pathology Chairs Program Directors Section recognize these competencies and are working to create new tools for training programs to deploy. Conclusions.—It is our recommendation that (1) every training program develop a formal educational strategy for management training, (2) greater opportunity and visibility be afforded for peer-reviewed publications on management topics in mainstream pathology literature, and (3) pathology milestones–oriented tools be developed to assist program directors and their trainees in developing this necessary knowledge and skills.

APA, Harvard, Vancouver, ISO, and other styles

42

Audcent, T., H. MacDonnell, J. Brenner, and L. Samson. "64. International child health (ICH) education in Canadian paediatric residency programss." Clinical & Investigative Medicine 30, no. 4 (August 1, 2007): 63. http://dx.doi.org/10.25011/cim.v30i4.2825.

Full text

Abstract:

A national survey was conducted of current ICH exposure and curriculum in pediatric residency programs. Our objectives were to quantify ICH teaching presently occurring, to identify how programs support trainees in undertaking ICH electives during their training, to determine attitudes towards ICH amongst paediatric program directors and chief residents across the country, and to identify barriers to ICH curriculum expansion within the post-graduate programs. A population census of all 44 chief residents and program directors from the 16 Canadian pediatric programs was undertaken. A self-administered survey was developed de novo for this study. Twenty-two qualitative and quantitative questions were developed under the following domains: demographics, program content, electives, attitudes and perceptions, barriers and future directions. Surveys were completed electronically. Descriptive statistics were used, and common themes were extracted from qualitative responses. The response rate was 65% (29 surveys), with 81% of the training programs represented. Seventy-three percent of the program directors, and 44% of the chief residents from across the country responded. Eighty-nine percent reported that their program did not have a formal curriculum in ICH. All respondents reported some ICH related educational sessions, however certain areas felt to be key were lacking. 80% agreed that electives should be encouraged as part of residency training, but 72% indicated lack of adequate funding for these electives. Overall, 86% agreed that ICH issues are important for paediatric trainees and 84% indicated that more emphasis should be placed on ICH in the paediatric resident curriculum. Eighty-six percent of respondents agreed that their program would be interested in new initiatives regarding ICH. The results of this survey demonstrate that although there are opportunities for ICH exposure in most paediatric training programs, formalized curriculum is lacking. The majority of programs indicated a willingness to support the integration of an ICH curriculum into their core educational components. The Association of Faculties of Medicine of Canada (AFMC). Towards a Medical Education Relevant to All : The Case for Global Health in Medical Education. A Report of the Global Health Resource Group. April 2006. Bateman C, et al. Bringing global issues to medical teaching. Lancet, 2001; 358:1539-42. Edwards R, et al. Understanding global health issues: are international health electives the answer? Medical Education, 2004; 38:688-690.

APA, Harvard, Vancouver, ISO, and other styles

43

Donayre Bohabot, Cecilia Cristina, Lina Iris Palacios-Serna, and Juan Diego Dávila Cisneros. "Intrinsic motivation according to developmental stages in post-pandemic students." Salud, Ciencia y Tecnología - Serie de Conferencias 3 (April 15, 2024): 706. http://dx.doi.org/10.56294/sctconf2024706.

Full text

Abstract:

Introduction: After the pandemic known as COVID19, education has been a cause of analysis and concern, both by the relevant authorities and also by the directors and teachers of educational institutions at different levels of education. In this sense, higher education has been deteriorated and students have been affected, not only economically but also psychologically, with students having low intrinsic motivation. Objective: to establish the association between the levels of intrinsic motivation and the stages of development that students in the first academic semester of a technological higher education institute have in the year 2023. Method: A quantitative approach was used, which was type non-experimental and descriptive. The studied population consisted of 114 students, selected through intentional non-probabilistic sampling according to the study programs offered by the institution. Results: The results indicated that there is no association between the levels of intrinsic motivation and the stages of development in the students (p>.05), since the population was made up of a heterogeneous group with respect to the ages of the registered students. in said academic semester. Conclusions: the level of development of intrinsic motivation is an element with a strong influence on all stages of development that students go through, since the desire for professional improvement predominates in them.

APA, Harvard, Vancouver, ISO, and other styles

44

Ringel, Matthew D., Elizabeth J. Murphy, and Stephen R. Hammes. "Compensation, Productivity, and Other Demographics of Academic Divisions of Endocrinology, Diabetes, and Metabolism." Journal of the Endocrine Society 3, no. 8 (June 7, 2019): 1485–502. http://dx.doi.org/10.1210/js.2019-00095.

Full text

Abstract:

Abstract The landscape for academic endocrinology divisions has continued to evolve rapidly;thus, finding reliable data that can be used as benchmarks has become more difficult. Resources are available for salary and relative value units, with the Association of American Medical Colleges, Medical Group Management Association, and Faculty Practice Solutions Center the most commonly used databases. However, details regarding how these data are collected and what they include are unclear. For example, does the income include bonus and/or incentive payments? How are work relative value units defined (individual rendering vs supervising advanced practitioners or fellows or residents)? How is a clinical full-time equivalent defined? In addition, other important data that would be relevant to running an academic division of endocrinology are not available from these, or any other resources, including support staff numbers and compensation or fellowship funding and training information. Therefore, an unmet need exists for reliable data that divisions can use to help shape their visions and goals. To address this demand, the Association of Endocrine Chiefs and Directors, in collaboration with the Endocrine Society, developed a detailed survey for members to address the financial, productivity, composition, and educational issues that they regularly face. Twenty academic institutions throughout the United States completed in the survey in 2018. In the present report, we have provided the results of the survey and some initial interpretations of the findings. Our hope is that the information presented will prove useful as academic endocrinology divisions continue to evolve.

APA, Harvard, Vancouver, ISO, and other styles

45

Hoekzema, Grant S., Lisa Maxwell, Joseph W. Gravel, Walter W. Mills, and William Geiger. "The Residency Performance Index: An Effort at Residency Quality Assessment and Improvement in Family Medicine." Journal of Graduate Medical Education 6, no. 4 (December 1, 2014): 756–59. http://dx.doi.org/10.4300/jgme-d-13-00355.1.

Full text

Abstract:

Abstract Background Residency programs are increasingly being asked to defend their quality, and that of the residents they produce. Yet “residency quality” is a construct that has not been well defined, with no accepted standards other than meeting accreditation standards. In 2009, the Association of Family Medicine Residency Directors developed a strategic plan that included the goal of raising the quality of family medicine training. Objective We describe the development of this quality improvement tool, which we called the residency performance index (RPI), and its first year of use by family medicine residency programs. We describe the use of the tool as a “dashboard” to facilitate program self-improvement. Intervention Using program metrics specific to family medicine training, and benchmark criteria for these metrics, the RPI was launched in 2012 to help programs identify strengths and areas for improvement in their educational activities and resident clinical experiences that could be tracked and reviewed as part of the annual program evaluation. Results Approximately 100 program directors began using the tool and 70 finished the process, and were provided aggregate data. Initial review of this experience revealed difficulties with collecting data, and lack of information on graduates' scope of practice. It also showed the potential usefulness of the tool as a program improvement mechanism. Conclusions The RPI is a new quality improvement tool for family medicine residency programs. Although some initial challenges need to be addressed, it has the promise to aid family medicine residency in its internal improvement efforts.

APA, Harvard, Vancouver, ISO, and other styles

46

Nyamoma, Felistus. "Co-curricular practices on prevention of substance abuse among secondary school students in Kakamega County – Kenya." Journal of Social Sciences and Economics 2, no. 1 (June 30, 2023): 35–43. http://dx.doi.org/10.61363/jsse.v2i1.78.

Full text

Abstract:

The critical need everywhere in the 21 century world is to prepare students to lead healthy and fulfilling lives by providing them with relevant educational programmes inclusive of co-curricular practices. The study evaluated influence of co-curricular practices on effectiveness of substance abuse preventive intervention among secondary school students in Kakamega County. It adopted a cross-sectional survey design. The target population was 59675 form three students, 1080 class teachers, 530 G/Cteachers and 12 sub-county directors in the study area. Simple random and purposive sampling techniques were used to select the sample size; 381 students, 108 class teachers, 53 G/C and 12 sub-county directors of education. Structured questionnaires, focus group discussion guide and interview guide were used to collect data which was subjected to descriptive and inferential analysis using Statistical Package for Social Sciences. Based on the correlation results, the study established that there is a positive association between co-curricular practices and effectiveness of substance abuse preventive interventions in the study area. From the regression results, co-curricular practices is a significant predictor. Therefore at 95% confidence limit co-curricular practices have statistically significant influence on effectiveness of substance abuse preventive intervention. The practices range from competitive games and sports, with the highest influence, followed by time allocated, frequency of participation, down to stars in co-curricular and lastly clubs. Overall, the study concludes that the success of effectiveness of substance abuse prevention is dependent on co-curricular practices. The intervention range from school administration, school location, open communication and finally random checks

APA, Harvard, Vancouver, ISO, and other styles

47

Petranović, Martina. "Dinka Jeričević – the Iron Lady of Croatian Scenic Design." Radovi Zavoda za hrvatsku povijest Filozofskoga fakulteta Sveučilišta u Zagrebu 55, no. 1 (December 20, 2023): 167–81. http://dx.doi.org/10.17234/radovizhp.55.10.

Full text

Abstract:

The paper examines the theatrical career and artistic expression of Dinka Jeričević (Vukovar, 26 September 1947), a distinguished Croatian scenic designer and one of the few women in the profession, especially at the time of her formative years, when she also served as the only female technical director in Croatian theatres. Creating over six hundred scenic designs, collaborating with the most prominent Croatian theatrical directors, and working in almost all Croatian theatres, as well as several theatres abroad, as both an in-house and guest designer, Jeričević significantly influenced and personally marked the history of Croatian scenic design over the last fifty years. Furthermore, her long-standing educational work with directors and producers at the Academy of Dramatic Arts in Zagreb and her passionate mentoring of emerging designers in theatre practice contributed greatly both to the education of numerous young theatre professionals and to shaping contemporary Croatian scenic design. Finally, by becoming actively involved in continuous and pertinent efforts of the Croatian Association of Artists of Applied Arts (ULUPUH) to improve the professional and legal status and working conditions of Croatian designers, she actively participated in the social betterment of Croatian scenic design(ers). Even though she is recognized and acknowledged in her professional environment, and presented with numerous prizes and awards, her career in the theatre has never been the subject of any scholarly analysis. The paper therefore attempts to address some of her design principles and contribute to the systematisation, valorisation and contextualisation of her multiple, diverse and outstanding artistic and professional accomplishments in national theatre.

APA, Harvard, Vancouver, ISO, and other styles

48

St. Louis, Joshua, Emma Worringer, and Wendy B. Barr. "Residency Setting Association With Resident Substance Use Disorder Training: A CERA Secondary Data Analysis." Family Medicine 52, no. 3 (March 6, 2020): 198–201. http://dx.doi.org/10.22454/fammed.2020.373152.

Full text

Abstract:

Background and Objectives: As the opioid crisis worsens across the United States, the factors that impact physician training in management of substance use disorders become more relevant. A thorough understanding of these factors is necessary for family medicine residency programs to inform their own residency curricula. The objective of our study was to identify factors that correlate with increased residency training in addiction medicine across a broad sample of family medicine residencies. Methods: We performed secondary analysis of a national family medicine residency program director survey conducted in 2015-2016 (CERA Survey PD-8). We obtained data from the Council of Academic Family Medicine Educational Research Alliance (CERA) Data Clearinghouse. We analyzed residency clinic site designation as a patient-centered medical home (PCMH), federally-qualified health center (FQHC), or both, for their correlation with faculty member possession of DEA-X buprenorphine waiver license, as well as required residency curriculum in addiction medicine. Results: Residency programs situated in an FQHC were more likely to have faculty members who possessed DEA-X buprenorphine waiver licenses (P=.025). Residency clinics that were both a PCMH as well as an FQHC also correlated strongly (P=.001). Furthermore, residencies with faculty who possessed a DEA-X license were significantly more likely to have a required curriculum in addiction medicine (P=.002). Conclusions: Our quantitative secondary analysis of CERA survey data of family medicine residency program directors revealed that resident training in addiction medicine is strongly correlated with both residency clinic setting (FQHC or FQHC/PCMH) as well as residency faculty possession of DEA-X licenses.

APA, Harvard, Vancouver, ISO, and other styles

49

Adams, George, Lennart Graebner, Anwar Sayed, Jana Vandrovcova, Alice Glaser, Deena Paul, James B. Bussel, and Nichola Cooper. "Cytokine Fluctuations in Immune Thrombocytopenia (ITP) over Time; Insights into the Pathogenesis and Evolution of the Disease." Blood 128, no. 22 (December 2, 2016): 2549. http://dx.doi.org/10.1182/blood.v128.22.2549.2549.

Full text

Abstract:

Abstract Background: Immune thrombocytopenia (ITP) is an autoimmune condition characterised by an isolated thrombocytopenia at the exclusion of any other causes. The prevailing paradigm for the pathogenesis of ITP is that it is caused by IgG auto-antibodies against platelet receptors. There is however good evidence that dysregulation of the cellular immune system is a major contributing factor. In particular it has been hypothesised that the cellular immune system has a role in perpetuating the disease although how this occurs is unclear. For this reason by understanding the cellular immune system in ITP we may be able to develop more targeted treatments for patients with refractory or resistant disease. Our aim was to investigate the alterations in the cellular immune system by measuring a selection of cytokines known to be associated with different T-cell immune responses (Th1, Th2, Th17 helper cell responses) in patients with ITP and look at how these changed over the course of the disease. Methods: Using a chromogenic assay we measured serum cytokine concentrations from 51 samples from 37 different patients with ITP and 15 healthy control subjects. Each sample was processed in duplicate. We selected to measure cytokines associated with key T-helper cell responses. These included IFNγ, IL-12, IL-2 (Th1 helper cell responses), IL-4, IL-5, IL-10, IL-13 (Th2 helper responses), IL-17 (Th17 helper responses) as well as TNFα, IL6, IL1b, EGF, VEGF, GCSF and GM-CSF. The platelet counts in our patient cohort ranged from 1 to 345x109/L. Samples were taken at different time points, ranging from 5 days to 12,753 days from diagnosis. Primary component analysis (PCA) was used to explore cytokine patterns within the ITP population and directed analysis using partial least square-discriminate analysis (PLS-DA) was used to identify which cytokines altered with the platelet count. Factor Analysis (FA) was used to distinguish which cytokines showed redundant variance. Finally Least-square non-parametric regression was used to plot cytokines levels (pg/ml) versus time from diagnosis (days) in a model curve. Results: Multivariate data analyses (PCA, PLS-DA) showed that patient samples had particularly marked differences in IL-12, IL-17, VEGF and IFNα when compared to controls. IL-17 and VEGF were much higher compared to controls (IL17 vs. controls; 17.2±5.0 vs. 4.75±0.0 pg/ml, VEGF vs. controls; 11.3 ±4.3 vs. 4.3 ±3.0 pg/ml) whereas IL-12 and IFNα where suppressed (IL-12 vs. controls; 119±100 vs. 554± 190pg/ml, IFNα vs. controls; 50±38 vs. 176±74pg/ml). Using Factor Analysis (FA) we also identified that IL-12, IFNα, IFNγ and TNFα had significant co-variance suggesting a common link whereas IL-17 was independent of other cytokines. From our PLS-DA model IL-1b and RANTES had the strongest correlation with platelet count, with both cytokines falling with the platelet count. The remaining cytokines did not show a strong correlation with platelet count. When plotted against time from diagnosis (in days) a subset of cytokines (IFNγ, IL-7, TNFα, GCSF, VEGF and IL-6) showed a marked rise from diagnosis with a continued increase only to peak after 2-3 years from diagnosis. They then declined slowly, reaching a baseline 10 years after diagnosis (Figure 1). In contrast, the remaining cytokines within the panel remained predominately flat (although still higher than controls) and unvaried over the time-course. Conclusion; Our findings suggests that the cell-mediated immune system is significantly altered in ITP with a particularly polarised cytokine pattern in keeping with a suppressed Th1 profile (including IL-12 and IFNγ level) and a heightened Th17 response (IL-17). This is different from published results of a skew towards a Th1 profile and may reflect the high proportion of patients with chronic disease in this cohort. We also demonstrate for the first time that there is a fluctuating pattern in the cytokine profile of patients with ITP over time with a sharp onset at the point of diagnosis presumably in response to some unknown stimulus and this subsequent rise continues (despite treatments) and evolves over years as opposed to weeks or months. These findings cast a new light onto a disease which until recently has been thought to be largely antibody mediated. Further evaluation is underway to establish whether a specific cell subset is responsible for the cytokine release and how this contributes to disease. Disclosures Bussel: Physicians Education Resource: Speakers Bureau; Boehringer Ingelheim: Research Funding; Prophylix Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; Immunomedics: Research Funding; Symphogen: Membership on an entity's Board of Directors or advisory committees; BiologicTx: Research Funding; Momenta Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Protalex: Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Eisai: Membership on an entity's Board of Directors or advisory committees, Research Funding; Genzyme: Research Funding; Sysmex: Research Funding; Cangene: Research Funding; UpToDate: Patents & Royalties; Rigel Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Ligand: Membership on an entity's Board of Directors or advisory committees, Research Funding; Shionogi: Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Cooper:Amgen Inc.: Consultancy, Honoraria, Other: Received honoraria for speaking at educational meetings ; GlaxoSmithKline: Consultancy, Honoraria, Other: Received honoraria for speaking at educational meetings ; Eisai: Consultancy, Honoraria, Other: Received honoraria for speaking at educational meetings; Imperial College BRC: Research Funding; National Organization for Rare Disorders: Research Funding; UK ITP support association: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

50

Ghesquieres, Herve, Youenn Drouet, Sarah Huet, Guillaume Cartron, Marie-Helene Delfau, Fritz Offner, Pauline Brice, Luc Xerri, Reda Bouabdallah, and Gilles A. Salles. "Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study." Blood 134, Supplement_1 (November 13, 2019): 2780. http://dx.doi.org/10.1182/blood-2019-130357.

Full text

Abstract:

Introduction: Genome wide-association studies (GWAS) identified specific constitutional single nucleotide polymorphisms (SNPs) at risk for follicular lymphoma (FL). Top SNP is localized in HLA region (rs12195582). Five genome wide significant loci have been identified outside of HLA region, including 11q23.3 (near CXCR5), 11q24.3 (near ETS1), 3q28 (near LPP), 18q21.33 (near BCL2), and 8q24 (near PVT1) in addition with three suggestive loci at 17q25.3 (near CYBC1), 3q13.33 (CD86), 18q12.3 (SLC14A2) (Skibola, Am J Hum Genet. 2014). We investigated if these nine known FL loci could affect response to immunochemotherapy, histological transformation and outcome of a subgroup of patients treated uniformly in the prospective PRIMA phase III study. Methods: Among the 1.193 patients included in the PRIMA study, 390 patients had genotyping of the nine SNPs associated with FL risk (HLA, rs12195582; CXCR5, rs4938573; ETS1, rs4937362; LPP, rs6444305; BCL2, rs17749561; PVT1, rs13254990; CYBC1, rs3751913; CD86, rs2681416; SLC14A2, rs11082438). DNA was extracted from peripheral blood mononuclear leukocytes before any treatment. The genotyping was performed using custom TaqMan genotyping assays as part of the FL GWAS (Skibola, Am J Hum Genet. 2014). Correlations between response to induction treatment, biopsy-proven histological transformation (HT) and progression free survival (PFS) were performed for the each nine SNP individually. We also computed a combined polygenic risk score (PRS) and the number of allele at risk (nbRA) using the 9 SNPs for each individual. The PRS is a weighted average of the number of risk alleles with the weights being the log of the odds-ratio (OR) reported in the FL GWAS (Skibola, Am J Hum Genet. 2014). Survival analyses were stratified on FLIPI score and randomized arm (rituximab maintenance or observation). Piecewise cox models with pre-specified cutoffs at 2 years and 5 years were used to study early and late relapses. This work is supported by the French NCI (INCA, PRT-K16-167). Results: Among the 390 patients who received immunochemotherapy in the PRIMA study, 173 were randomized in rituximab maintenance arm, 166 were observed and 51 were not randomized. Complete response (CR) and unconfirmed CR were achieved in 251 patients (68%) at the end of induction phase. HT was documented in 16 patients (18%) among the 91 patients who had a biopsy with histological documentation at relapse. With a median follow-up of 9.8 years, the 5-year PFS since registration date for the whole cohort was 57% (95%CI, 52-62), 71% (95%CI, 64-78) in the rituximab maintenance arm, 47% (95%CI, 40-56) in the observation arm, and 39% (95%CI, 27-56) for the patients not randomized, thereby confirming the results of the PRIMA study. SNP rs17749561 C>T (CC, n=326; CT+TT, n=61) at 18q21.33 near BCL2 (HRCT/TT: 2.13; 95%CI, 1.20-3.70, P=0.009) and SNP rs3751913 A>G (AA, n=292; AG+GG, n=90) at 17q25.3 near CYBC1 (HRAG/GG: 1.83; 95%CI, 1.12-2.99, P=0.016) influenced the quality of response after induction therapy (CR/CRu versus partial response, stable and progressive disease) after FLIPI stratification but not PRS and nbRA. HT was not influenced by the allele status of the 9 individual SNPs, nor PRS and nbRA with the limitation of the low numbers of events. rs3751913 A>G near CYBC1 influenced PFS with 5-year PFS rates of 55%, 63% and 30% for patients with AA (n=293), AG (n=80) and GG (n=10) (P=0.036), respectively, with the limitation of the low number of patients with GG genotype. No association with PFS was observed for the remaining SNPs and when the 9 alleles were combined in a PRS or nbRA analyzed as continuous variables or per quantiles. We then investigated the susceptibility SNPs could influence early or late relapse. Using Piecewise cox models, we globally did not observe any influence on the risk of relapse in the 2 years after registration, between 2 and 5 years and after 5 years of SNPs analyzed individually by PRS or nbRA. Conclusions: Two susceptibility SNPs for FL identify by GWAS near BCL2 and CYBC1 genes influenced the quality of the response after induction therapy by immunochemotherapy. CYBC1 gene codes for cytochrome b-245 chaperone 1, a member of multi-subunit phagocyte NADPH oxidase. These results require replication in an independent cohort. Overall, susceptibility SNPs for FL are not associated with HT and PFS in this cohort of patients. Disclosures Cartron: Roche, Celgene: Consultancy; Sanofi, Gilead, Janssen, Roche, Celgene: Honoraria. Brice:Millennium Takeda: Research Funding; Takeda France: Consultancy, Honoraria; BMS: Honoraria. Salles:Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Autolus: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Novartis, Servier, AbbVie, Karyopharm, Kite, MorphoSys: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Amgen: Honoraria, Other: Educational events; BMS: Honoraria; Roche, Janssen, Gilead, Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Epizyme: Consultancy, Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Unitarian Educational Directors Association'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles